

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

D6

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/70		A2	(11) International Publication Number: WO 97/40193 (43) International Publication Date: 30 October 1997 (30.10.97)
<p>(21) International Application Number: PCT/EP97/02002</p> <p>(22) International Filing Date: 21 April 1997 (21.04.97)</p> <p>(30) Priority Data: 96870053.4 19 April 1996 (19.04.96) EP (34) Countries for which the regional or international application was filed: BE et al.</p> <p>(71) Applicant (for all designated States except US): INNOGENETICS N.V. [BE/BE]; Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): STUYVER, Lieven [BE/BE]; Holestraat 8, B-9552 Herzele (BE). ROSSAU, Rudi [BE/BE]; Wilgehoestraat 45, B-2180 Ekeren (BE). MAERTENS, Geert [BE/BE]; Zilversparrenstraat 64, B-8310 Brugge (BE).</p> <p>(74) Agent: DE CLERCQ, Ann; Innogenetics N.V., Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>	
<p>(54) Title: METHOD FOR TYPING AND DETECTING HBV</p> <p>(57) Abstract</p> <p>The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from Figure 1, and with said probes being applied to known locations on a solid support and with said probes being capable of hybridizing to the polynucleic acids of the sample under the same hybridization and wash conditions, or with said probes hybridizing specifically with a sequence complementary to any of said target sequences, or a sequence wherein T of said target sequence is replaced by U; and detecting the hybrids formed; and inferring the HBV genotype and/or mutants present in said sample from the differential hybridization signal(s) obtained. The invention further relates to sets of nucleotide probes and possibly primers useful in said methods as well as to their use in a method for typing and/or detecting HBV and to assay kits using the same.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Method for typing and detecting HBV

The present invention relates to the field of Hepatitis B virus (HBV) diagnosis. More particularly, the present invention relates to the field of HBV genotyping and/or determination of the presence of HBV mutants in test samples.

5 The present invention relates particularly to a method for the rapid and reliable detection of HBV mutants and/or genotypes occurring in a test sample using specific sets of probes optimized to function together in a reverse-hybridisation assay.

10 Hepatitis B virus is a small enveloped DNA virus of approximately 3200 bp long. Historically it has been characterized on the basis of immunological reaction of the HBsAg with sets of monoclonal antibodies. Isolates were described as *a*, indicating the common determinant for all different subtypes, followed by subtype-specific combinations: *dw*, *dr*, *yw*, or *yr*. The latter are mutually exclusive pairs of determinants, covering the HBsAg amino acids 122 (*d*=lys, *y*=arg) and 160
15 (*w*=lys, *r*=arg). Several subdeterminants for *w* exist and can be ascribed to the appearance of certain amino acid variants at codon 127. More recently, a genetic classification has been proposed, based on molecular analysis of the virus. This kind of analysis showed that in total six different genotypes exist, indicated from A to F, with a maximum genetic divergence of 8% when comparing complete
20 genomes (reviewed by Magnius and Norder, 1995).

25 The genetic variability of HBV might be clinically important. Indeed, the genome variability might include some mechanisms by which HBV avoids immune clearance, and hence induces chronic infection. An important protein marker in inducing immune tolerance, virus elimination, and chronic infection, is HBeAg. The expression of this protein is strictly controlled both at the transcriptional and translational level (Li et al., 1993; Okamoto et al., 1990; Yuan et al., 1995; Sato et al., 1995). Therefore, in the natural course of HBV infection, a well characterized stage of the disease is indicated as HBe-negative chronic hepatitis B (reviewed by Hadziyannis S.J., 1995). This phase is mostly due to the
30 appearance of preCore translational stop codon mutations. The overall genetic

variability determines the frequency and physical location on the viral genome where these translational stop-codon mutations appear. The transcriptional regulation was proposed to be the mechanism for genotype A (and possibly also F), whereas the translational control was more likely to be found in the other 5 genotypes (Li et al.; 1993; Sato et al., 1995). Contradictory to the translational regulation, it was shown that the transcriptional regulation was unable to block the HBeAg expression completely and was therefore proposed to categorize the phenotype of this mutant as HBe-suppressed, rather than as HBe-negative (Takahashi et al., 1995). In any case, these preCore mutants would lead to a 10 destruction of the pre-existing balance between HBeAg in circulation and the HBc-derived peptides presented by class I HLA molecules on the surface of infected hepatocytes, thereby diminishing the suppressive effect of HBeAg on T cells, finally resulting in partial liberation of core-specific CTLs and leading to apoptosis of the infected hepatocytes. In general, after the emergence of the HBe-minus variants, 15 the course of the viral infection is characterized by the progression of chronic hepatitis, which may lead to the development of cirrhosis and hepatocellular carcinoma (Hadziyannis, 1995).

Another issue for which the genetic variability or genotyping of the virus might be of relevance is in the development of vaccines where the response may 20 be mediated by the virus type. Protection against HBV infection of all subtypes is conferred by antibodies to the common 'a' determinant of the HB surface antigen (HBsAg). It has been shown that this 'a' determinant presents a number of epitopes, and that its tertiary structure is most important for its antigenicity. The most important region lies between amino acid 124 and 147, but can be extended 25 from amino acid 114 to 150. An adequate anti-HBs response, built up after vaccination, is in principle fully protective. Infection with a HBV strain harboring mutations in the 'a' determinant region might result in vaccine failure, because the vaccine-induced humoral immune response does not recognize the mutant HBsAg. The most common vaccine-associated escape mutants are the substitutions of a 30 glycine at position 145 to an arginine (G145R), K141E, and T126N. But a 2-aa insertion between aa position 122 and 123, and 8-aa insertion between aa 123

and 124 have also been found (Carman et al., 1990, 1995; Crawford, 1990; Waters et al., 1992).

Lamivudine is a (-) enantiomer of 3' thiacytidine, a 2'3'-dideoxynucleoside analogue, and is known to be a potent inhibitor of HBV replication through inhibition of the reverse transcriptase (RT) activity of the HBV polymerase. Lamivudine treatment can result in histological improvements in chronic hepatitis patients, and when given pre- and post-liver transplantation, it can prevent graft reinfection (Honkoop et al., 1995; Naoumov et al., 1995). However, after treatment, a hepatitis flare-up can be observed in most patients, with ALT elevations and HBV DNA that becomes detectable again. This HBV DNA rebound is associated with a new quasi species equilibrium. In a few cases, virus breakthrough during therapy was observed, due to the selection of lamivudine resistant HBV strains. The exact nature of this breakthrough has been ascribed to the accumulation of mutations in the RT part of the Polymerase. A similar mechanism in the HIV RT polymerase has been found, where upon lamivudine treatment, mutations accumulate in the YMDD motif (Gao et al., 1993). This YMDD motif is also present in the RT part of the HBV polymerase, and lamivudine-selected mutations in HBV have been found in this region (Tipples et al., 1996), as well as in other regions of the RT part of the polymerase (Ling et al., 1996). Penciclovir is another drug that has been shown to inhibit the reverse transcriptase activity of the HBV polymerase (Shaw et al., 1996), and mutations in the HBV polymerase may also be detected upon treatment with this drug.

From all this it can be concluded that the information on the following issues is essential for proper *in vitro* diagnosis, monitoring and follow-up of HBV infections:

- genotype;
- preCore mutations;
- vaccine escape mutations;
- RT gene mutations selected by treatment with drugs such as lamivudine and penciclovir.

To obtain all this information using existing technologies is complicated, time-

consuming, and requires highly-skilled and experienced personnel.

It is thus an aim of the present invention to develop a rapid and reliable detection method for determination of the presence or absence of one or more HBV genotypes possibly present in a biological sample.

5 More particularly, it is an aim of the present invention to develop a rapid and reliable detection method for determination of the presence or absence of one or more variations in the HBV preS1 region and/or in the HBsAg region representing one or more HBV genotypes possibly present in a biological sample in one single experiment.

10 More particularly, it is an aim of the present invention to develop a rapid and reliable detection method for determination of the presence or absence of one or more HBV mutants possibly present in a biological sample in one single experiment.

15 More particularly, it is an aim of the present invention to develop a rapid and reliable detection method for determination of one or more mutations in the preCore region of HBV possibly present in a biological sample in one single experiment.

20 More particularly, it is an aim of the present invention to develop a rapid and reliable detection method for determination of one or more mutations in the HBsAg region of HBV possibly present in a biological sample in one single experiment.

More particularly, it is an aim of the present invention to develop a rapid and reliable detection method for determination of one or more mutations in the polymerase (pol) gene region of HBV possibly present in a biological sample in one single experiment.

25 More particularly, it is an aim of the present invention to develop a rapid and reliable detection method for the simultaneous determination of one or several HBV genotypes in combination with one or several HBV mutants possibly present in a biological sample in one single experiment.

30 It is also an aim of the present invention to provide a genotyping assay or method which allows to infer the nucleotide sequence at codons of interest and/or the HBV mutants of interest, and/or infer the HBV genotype possibly present in a

biological sample.

Even more particularly it is also an aim of the present invention to provide a genotyping assay allowing the detection of the different HBV mutants and genotypes in one single experimental setup.

5 It is another aim of the present invention to select particular probes able to discriminate one or more HBV mutations in one of the above mentioned regions of the HBV genome and/or able to discriminate one or more HBV genotypes.

It is more particularly an aim of the present invention to select particular probes able to discriminate wild-type HBV from mutant HBV sequences.

10 It is also an aim of the present invention to select particular probes able to discriminate wild-type and polymorphic variants of HBV from mutant HBV sequences.

It is also an aim of the present invention to select particular probes able to discriminate HBV genotype sequences.

15 It is moreover an aim of the present invention to combine a set of selected probes able to genotype HBV and/or discriminate different HBV mutants possibly present in a biological sample, whereby all probes can be used under the same hybridisation and wash conditions.

20 It is also an aim of the present invention to select primers enabling the amplification of the gene fragment(s) determining the HBV genomic mutations or variations of interest as discussed above.

The present invention also aims at diagnostic kits comprising said probes useful for developing such a genotyping assay and/or assays for detecting, monitoring or following-up HBV infection and/or assays for detecting HBV 25 mutations.

All the aims of the present invention have been met by the following specific embodiments.

As a solution to the above-mentioned problem that it is essential for proper diagnosis, monitoring and follow-up of HBV infection to have information on the 30 genotype of HBV present, the present invention provides an elegant way to tackle

problems of such complexity which involves resorting to a reverse hybridization approach (particularly on Line Probe Assays strips, as described by Stuyver et al., 1993). Using this technology it is possible to conveniently obtain all essential data in one test run. To achieve this goal, a set of probes needs to be designed and
5 assembled which can detect all relevant polymorphisms in the HBV gene regions of interest.

The present invention thus particularly relates to a method for determining the presence or absence of one or more HBV genotypes in a biological sample, comprising:

- 10 (i) if need be releasing, isolating or concentrating the polynucleic acids present in the sample;
- (ii) if need be amplifying the relevant part of a suitable HBV gene present in said sample with at least one suitable primer pair;
- (iii) hybridizing the polynucleic acids of step (i) or (ii) with at least two nucleotide probes hybridizing specifically to a HBV genotype specific target sequence chosen from Figure 1; with said probes being applied to known locations on a solid support and with said probes being capable of hybridizing to polynucleic acids of step (i) or (ii) under the same hybridization and wash conditions or with said probes hybridizing specifically with a sequence complementary to any of said target sequences, or a sequence wherein T of said target sequence is replaced by U;
- 15 (iv) detecting the hybrids formed in step (iii);
- (v) inferring the HBV genotype present in said sample from the differential hybridization signal(s) obtained in step (iv).

The genotype specific target sequences can be any nucleotide variation appearing upon alignment of the different HBV genomes that permits classification of a certain HBV isolate as a certain genotype (see Figure 1).

30 The expression "relevant part of a suitable HBV gene" refers to the part of the HBV gene encompassing the HBV genotype specific target sequence chosen from Figure 1 to be detected.

According to a preferred embodiment of the present invention, step (iii) is performed using a set of at least 2, preferably at least 3, more preferably at least 4 and most preferably at least 5 probes all meticulously designed such that they show the desired hybridization results, when used in a reverse hybridisation assay 5 format, more particularly under the same hybridization and wash conditions implying that each of said probes is able to form a complex upon hybridisation with its target sequence present in the polynucleic acids of the sample as obtained after step (i) or (ii).

The numbering of the HBV gene encoded amino acids and nucleotides is as 10 generally accepted in literature.

More particularly, the present invention relates to a set of at least 2 probes allowing the detection of a genotype specific variation, possibly also including one or more probes allowing the detection of a wild-type sequence, a polymorphic or a mutated sequence at any one of the nucleotide positions showing a sequence 15 diversity upon alignment of all known or yet to be discovered HBV sequences as represented in Figure 1 for all complete HBV genomes found in the EMBL/NCBI/DDBJ/Genbank.

The sets of probes according to the present invention have as a common characteristic that all the probes in said set are designed so that they can be used 20 together in a reverse-hybridization assay, more particularly under similar or identical hybridization and wash conditions as indicated above and below.

Selected sets of probes according to the present invention include probes which allow to differentiate any of the HBV genotype specific nucleotide changes as represented in Figure 1, preferably in the preS1 or HBsAg region of HBV. Said 25 probes being characterized in that they can function in a method as set out above.

In order to solve the above-mentioned problem of obtaining information on the possible presence of HBV mutants in a given sample, the present invention provides an elegant way to tackle this problem which involves residing to a reverse hybridisation approach (particularly on Line Probe Assays strips, as described by 30 Stuyver et al., 1993). Using this technology it is possible to conveniently obtain all essential data in one test run. To achieve this goal, a set of probes needs to be

designed and assembled which can detect all relevant mutations and possibly also wild-type sequences or polymorphisms in the HBV gene regions of interest.

Another particularly preferred embodiment of the present invention thus is a method for determining the presence or absence of one or more HBV mutants in a biological sample, comprising:

- (i) if need be releasing, isolating or concentrating the polynucleic acids present in the sample;
- (ii) if need be amplifying the relevant part of a suitable HBV gene present in said sample with at least one suitable primer pair;
- 10 (iii) hybridizing the polynucleic acids of step (i) or (ii) with at least two nucleotide probes hybridizing specifically to a HBV mutant target sequence chosen from Figure 1, with said probes being applied to known locations on a solid support and with said probes being capable of hybridizing to the polynucleic acids of step (i) or (ii) under the same hybridization and wash conditions, or with said probes hybridizing specifically with a sequence complementary to any of said target sequences, or a sequence wherein T of said target sequence is replaced by U and with said set of probes possibly also comprising one or more wild-type HBV probes corresponding with the respective mutated HBV target sequence;
- 15 (iv) detecting the hybrids formed in step (iii);
- (v) inferring the HBV mutant(s) present in said sample from the differential hybridization signal(s) obtained in step (iv).

It is to be understood that the term "mutant target sequence" not only covers the sequence containing a mutation, but also the corresponding wild-type sequence. The HBV mutant target sequence according to the present invention can be any sequence including a HBV mutated codon known in the art or yet to be discovered. Particularly preferred HBV mutant target regions are set out below.

In order to solve the problem as referred to above of obtaining information on the essential issues for proper diagnosis of HBV (namely genotype and different mutations particularly mutations in the preCore region, vaccine escape mutations and RT gene mutations selected by treatment with drugs such as lamivudine and

penciclovir), the present invention provides a particularly elegant way to obtain such complex information.

Moreover, careful analysis of the data obtained by the present inventors clearly revealed that combining the information concerning the preCore and escape 5 mutants with data on the genotype is essential to allow adequate interpretation of the results. Hence it is highly advantageous to be able to produce all relevant data simultaneously.

In this method for diagnosing HBV mutants, preferably in combination with 10 HBV genotyping, a set of probes selected as defined above may be used, wherein said set of probes is characterized as being chosen such that for a given HBV mutation, the following probes are included in said set :

- at least one probe for detecting the presence of the mutated nucleotide(s) at said position;
- at least one probe for detecting the presence of the wild-type nucleotide(s) 15 at said position;
- possibly also (an) additional probe(s) for detecting wild-type polymorphisms at positions surrounding the mutation position.

Inclusion of the latter two types of probes greatly contributes to increasing the sensitivity of said assays as demonstrated in the examples section.

20 Selected sets of probes according to the present invention include at least one probe, preferably at least two probes, characterizing the presence of a HBV mutation at nucleotide positions chosen from the preCore region of HBV, more particularly from the following list of codons susceptible to mutations in the HBV preCore region, such as codon 15 in genotype A, and for all genotypes: codon 28, 25 codon 29, and codon 28 and 29, or in the preCore promoter region (see Figure 1).

Said probes being characterized in that they can function in a method as set out above.

An additional embodiment of the present invention includes at least one 30 probe, preferably at least two probes, characterizing the presence of a vaccine escape mutation in codon positions chosen from the HBsAg region of HBV, more particularly from the list of codons susceptible to mutations in the HBV HBsAg

region, such as at codons 122, 126, 141, 143, 144 or 145 (see Figure 1).

An additional embodiment of the present invention includes at least one probe, preferably at least two probes, characterizing the presence of a mutation in the RT pol gene region of HBV, that gives rise to resistance to drugs such as lamivudine and penciclovir, for instance mutation of M to V or to I at position 552 (in the YMDD motif), mutation of V to I at position 555, mutation of F to L at position 514, mutation of V to L at position 521, mutation of P to L at position 525 and mutation of L to M at position 528 (see Figure 1).

In a selected embodiment, a combination of at least two oligonucleotide probes is used and said combination of probes hybridizes specifically to at least two of the following groups of target sequences:

- a mutant target sequence chosen from the HBV RT pol gene region,
- a mutant target sequence chosen from the HBV preCore region,
- a mutant target sequence chosen from the HBsAg region of HBV,
- a HBV genotype-specific target sequence.

For instance, an embodiment involves hybridizing with at least one nucleotide probe hybridizing specifically to a genotype specific target sequence chosen from Figure 1 and at least one nucleotide probe hybridizing specifically to a HBV mutant target sequence chosen from Figure 1.

Another selected embodiment involves, for instance, hybridizing with at least one nucleotide probe hybridizing specifically to a genotype specific target sequence chosen from Figure 1 and at least one nucleotide probe hybridizing specifically to a HBV mutant target sequence chosen from the RT pol gene region as represented in Figure 1.

Another selected embodiment involves, for instance, hybridizing with at least one nucleotide probe hybridizing specifically to a genotype specific target sequence chosen from Figure 1 and at least one nucleotide probe hybridizing specifically to a HBV mutant target sequence chosen from the preCore region as represented in Figure 1.

Another selected embodiment involves, for instance, hybridizing with at least one nucleotide probe hybridizing specifically to a genotype specific target sequence

chosen from Figure 1 and at least one nucleotide probe hybridizing specifically to a HBV vaccine escape mutant target sequence within the HBsAg region as represented in Figure 1.

5 In a selected embodiment, a combination of at least three oligonucleotide probes is used and said combination of probes hybridizes specifically to at least three of the following groups of target sequences:

- 10 a mutant target sequence chosen from the HBV RT pol gene region,
a mutant target sequence chosen from the HBV preCore region,
a mutant target sequence chosen from the HBsAg region of HBV,
a HBV genotype-specific target sequence.

15 For instance, an embodiment involves hybridizing with at least one nucleotide probe hybridizing specifically to a genotype specific target sequence chosen from Figure 1, and at least one nucleotide probe hybridizing specifically to a HBV mutant target sequence chosen from the preCore region as represented in Figure 1, and at least one nucleotide probe hybridizing specifically to a HBV vaccine escape mutant target sequence chosen from the HBsAg region as represented in Figure 1.

20 For instance, another embodiment involves hybridizing with at least one probe hybridizing specifically to a mutant target sequence from the HBV RT pol gene region of HBV, and at least one probe hybridizing specifically to a mutant target sequence from the HBsAg region of HBV, and at least one probe hybridizing specifically to a genotype-specific target sequence from the HBsAg region of HBV. According to this embodiment, the relevant part of the HBV genome can be amplified by use of one primer pair, for instance HBPr 75 and HBPr 94.

25 In a selected embodiment, a combination of at least four oligonucleotide probes is used and said combination of probes hybridizes specifically to all of the following groups of target sequences:

- 30 a mutant target sequence chosen from the HBV RT pol gene region,
a mutant target sequence chosen from the HBV preCore region,
a mutant target sequence chosen from the HBsAg region of HBV,
a HBV genotype-specific target sequence.

Particularly preferred embodiments of the invention thus include a set of probes as set out above comprising at least one, preferably at least two, at least three, at least four or more probe(s) for targeting one, preferably two, three or more nucleotide changes appearing in the alignment of HBV genomes as represented in Figure 1.

Even more preferred selected sets of probes according to the present invention include probes derived from two of the same or different regions of HBV bearing HBV mutated nucleotides, or in addition also a third (set of) probe(s) characterizing the presence of a third HBV mutation at any of the positions shown in Figure 1, or particular combinations thereof.

Particularly preferred is also a set of probes which allows simultaneous detection of HBV mutations at codons 15, 28 and 29 in the preCore region, possibly in combination with mutations in the preCore promoter regions, in combination with mutations at codons 122, 126, 141, 143, 144, 145 in the HBsAg region, possibly also in combination with mutations in the HBV pol gene at codons 514, 521, 525, 528, 552 or 555.

In the instances where the alignment of HBV genomes of Figure 1 is referred to in this invention, it should be construed as referring to an alignment of all existing and future HBV genomes. The existing HBV genome sequences can be deduced from any database, such as the EMBL/NCBI/DDBJ/GENBANK database.

A preferred set of preCore, preS1, HBsAg and RT pol gene probes of this invention are the probes with SEQ ID NO 1 to 278 of Table 1 (see also Figure 1).

Particularly preferred sets of probes in this respect are shown in Figure 2 and in Figure 4. The probes in Figure 2 and in Figure 4 were withheld after a first selection for preCore, preS1, HBsAg and RT pol probes.

The probes of the invention are designed for obtaining optimal performance under the same hybridization conditions so that they can be used in sets of at least 2 probes for simultaneous hybridization. This highly increases the usefulness of these probes and results in a significant gain in time and labour. Evidently, when other hybridization conditions would be preferred, all probes should be adapted accordingly by adding or deleting a number of nucleotides at their extremities. It

should be understood that these concomitant adaptations should give rise to essentially the same result, namely that the respective probes still hybridize specifically with the defined target. Such adaptations might also be necessary if the amplified material should be RNA in nature and not DNA as in the case for the
5 NASBA system.

The selection of the preferred probes of the present invention is based on a reverse hybridization assay format using immobilized oligonucleotide probes present at distinct locations on a solid support. More particularly the selection of preferred probes of the present invention is based on the use of the Line Probe
10 Assay (LiPA) principle which is a reverse hybridization assay using oligonucleotide probes immobilized as parallel lines on a solid support strip (Stuyver et al. 1993; international application WO 94/12670). This approach is particularly advantageous since it is fast and simple to perform. The reverse hybridization format and more particularly the LiPA approach has many practical advantages as compared to other
15 DNA techniques or hybridization formats, especially when the use of a combination of probes is preferable or unavoidable to obtain the relevant information sought.

It is to be understood, however, that any other type of hybridization assay or format using any of the selected probes as described further in the invention, is also covered by the present invention.

20 The reverse hybridization approach implies that the probes are immobilized to certain locations on a solid support and that the target DNA is labelled in order to enable the detection of the hybrids formed.

The following definitions serve to illustrate the terms and expressions used in the present invention.

25 The term "genetic analysis" refers to the study of the nucleotide sequence of the genome of HBV by any appropriate technique.

The term "HBV mutant" refers to any HBV strain harbouring genomic variations with serological, genetical or clinical consequences.

30 The term "vaccine escape mutant" is reviewed in the introduction section and in Example 7. The most important region lies between amino acid 124 and 147 of the HBsAg region, but can be extended from amino acid 114 to 150.

The term "mutant resistant to drugs such as lamivudine and penciclovir" is reviewed in the introduction section and in Example 8.

The term "HBV genotype" refers to HBV strains with an intergenotype variation of 8% or more based on a comparison of complete genomes.

5 The target material in the samples to be analyzed may either be DNA or RNA, e.g. genomic DNA, messenger RNA, viral RNA or amplified versions thereof. These molecules are also termed polynucleic acids.

It is possible to use genomic DNA or RNA molecules from samples susceptible of containing HBV in the methods according to the present invention.

10 Well-known extraction and purification procedures are available for the isolation of RNA or DNA from a sample (f.i. in Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbour Laboratory Press (1989)).

15 The term "probe" refers to single stranded sequence-specific oligonucleotides which have a sequence which is complementary to the target sequence to be detected.

20 The term "target sequence" as referred to in the present invention describes the nucleotide sequence of a part of wild-type, polymorphic or mutant HBV gene sequence to be specifically detected by a probe according to the present invention. The polymorphic sequence may encompass one or more polymorphic nucleotides; the mutant sequence may encompass one or more nucleotides that are different from the wild-type sequence. It is to be understood that the term "mutant target sequence" not only covers the sequence containing a mutation, but also the corresponding wild-type sequence. Target sequences may generally refer to single nucleotide positions, codon positions, nucleotides encoding amino acids or to sequences spanning any of the foregoing positions. In the present invention said target sequence often includes one, two or more variable nucleotide positions. In the present invention polynucleic acids detected by the probes of the invention will comprise the target sequence against which the probe is detected.

25 It is to be understood that the complement of said target sequence is also a suitable target sequence in some cases. The target sequences as defined in the present invention provide sequences which should at least be complementary to

the central part of the probe which is designed to hybridize specifically to said target region. In most cases the target sequence is completely complementary to the sequence of the probe.

The term "complementary" as used herein means that the sequence of the single stranded probe is exactly the (inverse) complement of the sequence of the single-stranded target, with the target being further defined as the sequence where the mutation to be detected is located.

Since the current application requires the detection of single basepair mismatches, stringent conditions for hybridization are required, allowing in principle only hybridization of exactly complementary sequences. However, variations are possible in the length of the probes (see below). It should also be noted that, since the central part of the probe is essential for its hybridization characteristics, possible deviations of the probe sequence versus the target sequence may be allowable towards head and tail of the probe when longer probe sequences are used. These variations, which may be conceived from the common knowledge in the art, should however always be evaluated experimentally, in order to check if they result in equivalent hybridization characteristics as the exactly complementary probes.

Preferably, the probes of the invention are about 5 to 50 nucleotides long, more preferably from about 10 to 25 nucleotides. Particularly preferred lengths of probes include 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. The nucleotides as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridisation characteristics.

Probe sequences are represented throughout the specification as single stranded DNA oligonucleotides from the 5' to the 3' end. It is obvious to the man skilled in the art that any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U).

The probes according to the invention can be prepared by cloning of recombinant plasmids containing inserts including the corresponding nucleotide

sequences, if need be by cleaving the latter out from the cloned plasmids upon using the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight. The probes according to the present invention can also be synthesized chemically, for instance by the conventional phospho-triester method.

5 The term "solid support" can refer to any substrate to which an oligonucleotide probe can be coupled, provided that it retains its hybridization characteristics and provided that the background level of hybridization remains low. Usually the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead) or a chip. Prior to application to the
10 membrane or fixation it may be convenient to modify the nucleic acid probe in order to facilitate fixation or improve the hybridization efficiency. Such modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH₂ groups, SH groups, carboxylic groups, or coupling with biotin, haptens or proteins.

15 The term "labelled" refers to the use of labelled nucleic acids. Labelling may be carried out by the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki et al. (1988) or Bej et al. (1990) or labelled primers, or by any other method known to the person skilled in the art. The nature of the label may be isotopic (³²P, ³⁵S, etc.) or non-isotopic (biotin, digoxigenin, etc.).

20 The term "primer" refers to a single stranded oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied. The length and the sequence of the primer must be such that they allow to prime the synthesis of the
25 extension products. Preferably the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions of primer use such as temperature and ionic strength.

30 The expression "suitable primer pair" in this invention refers to a pair of primers allowing the amplification of part or all of the HBV gene for which probes are immobilized.

The fact that amplification primers do not have to match exactly with the corresponding template sequence to warrant proper amplification is amply documented in the literature (Kwok et al., 1990).

The amplification method used can be either polymerase chain reaction
5 (PCR; Saiki et al., 1988), ligase chain reaction (LCR; Landgren et al., 1988; Wu &
Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA;
Guatelli et al., 1990; Compton, 1991), transcription-based amplification system
(TAS; Kwok et al., 1989), strand displacement amplification (SDA; Duck, 1990;
Walker et al., 1992) or amplification by means of Q β replicase (Lizardi et al., 1988;
10 Lomeli et al., 1989) or any other suitable method to amplify nucleic acid molecules
known in the art.

The oligonucleotides used as primers or probes may also comprise nucleotide
analogues such as phosphorothiates (Matsukura et al., 1987),
alkylphosphorothiates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al.,
15 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al.,
1984).

As most other variations or modifications introduced into the original DNA
sequences of the invention these variations will necessitate adaptions with respect
to the conditions under which the oligonucleotide should be used to obtain the
20 required specificity and sensitivity. However the eventual results of hybridisation
will be essentially the same as those obtained with the unmodified
oligonucleotides.

The introduction of these modifications may be advantageous in order to
positively influence characteristics such as hybridization kinetics, reversibility of the
25 hybrid-formation, biological stability of the oligonucleotide molecules, etc.

The "sample" may be any biological material taken either directly from the
infected human being (or animal), or after culturing (enrichment). Biological material
may be e.g. expectorations of any kind, bronchoelavages, blood, skin tissue,
biopsies, sperm, lymphocyte blood culture material, colonies, liquid cultures, faecal
30 samples, urine etc.

The sets of probes of the present invention will include at least 2, 3, 4, 5,

6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30 or more probes. Said probes may be applied in two or more
(possibly as many as there are probes) distinct and known positions on a solid
substrate. Often it is preferable to apply two or more probes together in one and
the same position of said solid support.

5 For designing probes with desired characteristics, the following useful
guidelines known to the person skilled in the art can be applied.

Because the extent and specificity of hybridization reactions such as those
described herein are affected by a number of factors, manipulation of one or more
10 of those factors will determine the exact sensitivity and specificity of a particular
probe, whether perfectly complementary to its target or not. The importance and
effect of various assay conditions, explained further herein, are known to those
skilled in the art.

15 The stability of the [probe : target] nucleic acid hybrid should be chosen to
be compatible with the assay conditions. This may be accomplished by avoiding
long AT-rich sequences, by terminating the hybrids with G:C base pairs, and by
designing the probe with an appropriate Tm. The beginning and end points of the
probe should be chosen so that the length and %GC result in a Tm about 2-10°C
higher than the temperature at which the final assay will be performed. The base
20 composition of the probe is significant because G-C base pairs exhibit greater
thermal stability as compared to A-T base pairs due to additional hydrogen
bonding. Thus, hybridization involving complementary nucleic acids of higher G-C
content will be stable at higher temperatures.

Conditions such as ionic strength and incubation temperature under which
25 a probe will be used should also be taken into account when designing a probe. It
is known that hybridization will increase as the ionic strength of the reaction
mixture increases, and that the thermal stability of the hybrids will increase with
increasing ionic strength. On the other hand, chemical reagents, such as
30 formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds, will increase
the stringency of hybridization. Destabilization of the hydrogen bonds by such
reagents can greatly reduce the Tm. In general, optimal hybridization for synthetic

oligonucleotide probes of about 10-50 bases in length occurs approximately 5°C below the melting temperature for a given duplex. Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity.

5 It is desirable to have probes which hybridize only under conditions of high stringency. Under high stringency conditions only highly complementary nucleic acid hybrids will form; hybrids without a sufficient degree of complementarity will not form. Accordingly, the stringency of the assay conditions determines the amount of complementarity needed between two nucleic acid strands forming a
10 hybrid. The degree of stringency is chosen such as to maximize the difference in stability between the hybrid formed with the target and the nontarget nucleic acid. In the present case, single base pair changes need to be detected, which requires conditions of very high stringency.

The length of the target nucleic acid sequence and, accordingly, the length
15 of the probe sequence can also be important. In some cases, there may be several sequences from a particular region, varying in location and length, which will yield probes with the desired hybridization characteristics. In other cases, one sequence may be significantly better than another which differs merely by a single base. While it is possible for nucleic acids that are not perfectly complementary to
20 hybridize, the longest stretch of perfectly complementary base sequence will normally primarily determine hybrid stability. While oligonucleotide probes of different lengths and base composition may be used, preferred oligonucleotide probes of this invention are between about 5 to 50 (more particularly 10-25) bases in length and have a sufficient stretch in the sequence which is perfectly
25 complementary to the target nucleic acid sequence.

Regions in the target DNA or RNA which are known to form strong internal structures inhibitory to hybridization are less preferred. Likewise, probes with extensive self-complementarity should be avoided. As explained above,
30 hybridization is the association of two single strands of complementary nucleic acids to form a hydrogen bonded double strand. It is implicit that if one of the two strands is wholly or partially involved in a hybrid that it will be less able to

participate in formation of a new hybrid. There can be intramolecular and intermolecular hybrids formed within the molecules of one type of probe if there is sufficient self complementarity. Such structures can be avoided through careful probe design. By designing a probe so that a substantial portion of the sequence of interest is single stranded, the rate and extent of hybridization may be greatly increased. Computer programs are available to search for this type of interaction.

5 However, in certain instances, it may not be possible to avoid this type of interaction.

Standard hybridization and wash conditions are disclosed in the Materials & Methods section of the Examples. Other conditions are for instance 3X SSC (Sodium Saline Citrate), 20% deionized FA (Formamide) at 50°C.

10 Other solutions (SSPE (Sodium saline phosphate EDTA), TMACl (Tetramethyl ammonium Chloride), etc.) and temperatures can also be used provided that the specificity and sensitivity of the probes is maintained. If need be, slight modifications of the probes in length or in sequence have to be carried out to maintain the specificity and sensitivity required under the given circumstances.

15 In a more preferential embodiment, the above-mentioned polynucleic acids from step (i) or (ii) are hybridized with at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more of the above-mentioned target region specific probes, preferably with 5 or 6 probes, which, taken together, cover the "mutation region" of the relevant HBV gene.

20 The term "mutation region" means the region in the relevant HBV gene sequence where at least one mutation encoding a HBV mutant is located in a preferred part of this mutation region is represented in figure 1.

25 Apart from mutation regions as defined above the HBV wild-type or mutant genomes may also show polymorphic nucleotide variations at positions other than those referred to as genotype specific or mutant specific variated positions as shown in Figure 1.

30 Since some mutations may be more frequently occurring than others, e.g. in certain geographic areas or in specific circumstances (e.g. rather closed

communities) it may be appropriate to screen only for specific mutations, using a selected set of probes as indicated above. This would result in a more simple test, which would cover the needs under certain circumstances.

In order to detect HBV genotypes and/or HBV mutants with the selected set 5 of oligonucleotide probes, any hybridization method known in the art can be used (conventional dot-blot, Southern blot, sandwich, etc.).

However, in order to obtain fast and easy results if a multitude of probes are involved, a reverse hybridization format may be most convenient.

In a preferred embodiment the selected set of probes are immobilized to a 10 solid support in known distinct locations (dots, lines or other figures). In another preferred embodiment the selected set of probes are immobilized to a membrane strip in a line fashion. Said probes may be immobilized individually or as mixtures to delineated locations on the solid support.

A specific and very user-friendly embodiment of the above-mentioned 15 preferential method is the LiPA method, where the above-mentioned set of probes is immobilized in parallel lines on a membrane, as further described in the examples.

The invention also provides for a set of primers allowing amplification of the 20 region of the respective HBV gene to be detected by means of probes. Examples of such primers of the invention are given in Table 1 and Figure 1.

Primers may be labelled with a label of choice (e.g. biotine). Different primer-based target amplification systems may be used, and preferably PCR-amplification, as set out in the examples. Single-round or nested PCR may be used.

The invention also provides a kit for detection and/or genetic analysis of HBV 25 genotypes and/or HBV mutants present in a biological sample comprising the following components:

- (i) when appropriate, a means for releasing, isolating or concentrating the polynucleic acids present in said sample;
- (ii) when appropriate, at least one suitable primer pair;
- 30 (iii) at least two of the probes as defined above, possibly fixed to a solid support;

- (iv) a hybridization buffer, or components necessary for producing said buffer;
 - (v) a wash solution, or components necessary for producing said solution;
 - (vi) when appropriate, a means for detecting the hybrids resulting from the preceding hybridization.
- 5 (vii) when appropriate, a means for attaching said probe to a known location on solid support.

The term "hybridization buffer" means a buffer enabling a hybridization reaction to occur between the probes and the polynucleic acids present in the sample, or the amplified products, under the appropriate stringency conditions.

10 The term "wash solution" means a solution enabling washing of the hybrids formed under the appropriate stringency conditions.

As illustrated in the Examples section, a line probe assay (LiPA) was designed for screening for HBV genotypes and/or HBV mutants. The principle of the assay is based on reverse hybridization of an amplified polynucleic acid fragment such as a biotinylated PCR fragment of the HBV gene onto short oligonucleotides. The latter hybrid can then, via a biotine-streptavidine coupling, 15 be detected with a non-radioactive colour developing system.

The following examples only serve to illustrate the present invention. These examples are in no way intended to limit the scope of the present invention.

FIGURE AND TABLE LEGENDS

Figure 1: Alignment of 35 complete HBV genomes. Isolates belonging to genotype A are: HBVXCPS, HBVADW, HVHEPB, S50225, HPBADWZCG; genotype B: HPBADW3, HPBADWZ, HPBADW1, HPBADW2; genotype C: HPBCGADR, 5 HBVADRM, HPBADRA, HPBCG, HEHBVAYR, HBVADR, HBVADR4, HPBADR1C, HPBADRC, HBVPREX, HPBETNC, HHVBC, HHVCCHA; genotype D: HBVAYWMCG, HBVAYWC, HBVAYWCI, HBVAYWE, HBVDNA, HPBHBVAA, XXHEPAV, HBVORFS; genotype E: HHVBE4, HHVBBAS; and genotype F: HHBF, HHVBFFOU, 10 HBVADW4A. To preserve alignment, several gaps were created in the alignment and are indicated with /. Positions of start and end of the different HBV encoded genes is indicated: HBsAg: hepatitis B surface antigen (small surface antigen); HBx: hepatitis B X protein; HB Pol: hepatitis B polymerase protein, encoding a terminal protein, a spacer, a RT/DNA polymerase region, and an RNase H activity; HBcAg: hepatitis B Core antigen; HBpreS1Ag: hepatitis B preS1 antigen (large surface 15 antigen); HBpreS2Ag: hepatitis B preS2 antigen (middle surface antigen). The position of the PCR primers is indicated with a large box over all 35 sequences. The polarity of the PCR primer can be deduced from the position of the name above these boxes: left = antisense primer; right = sense primer. LiPA probes are indicated with small boxes, the numbers of the probes are indicated next to the 20 probes or to the right of the alignment, and correspond to the probe numbers in Table 1.

Figure 2: LiPA HBV design. The content of a HBV LiPA strip is detailed. For each line number, the region on the viral genome is indicated, together with the genotype that is detected, the probe number that corresponds with the boxes from 25 the alignment in Figure 1, and the sequence of the probe.

Figure 3: Combined result of genotype determination in the preS1 region and preCore scanning on 24 samples. The interpretation of each sample is given under each strip. Probe reactivities on lines 3 to 14 are obtained from the preS1 PCR

fragment, probe reactivities on lines 15 to 27 are due to the preCore PCR fragment. Genotypes are indicated from A to F. The interpretation for the preCore region is as follows: W = wild type; M = mutant; I = indeterminate, meaning that no reactivity is observed, which is due to mutations that could not yet be detected with the selected probes; mix = mixture of wild type and mutant; interpretation of codon 15 is only relevant for genotype A, the absence of reactivity on HBPr 45 for genotypes B to F is of no use as is indicated with - (not applicable). Since the presence or absence of preCore mutations has effect on the serological HBeAg status, this is also indicated.

10 Figure 4: Probes used in HBV LiPA. Probes were designed for genotyping in the HBsAg region and for detection of drug resistance mutations in the YMDD motif (see also Figure 5), as well as for detection of mutations in the pre Core region (see also Figure 6).

15 Figure 5: Example of a LiPA assay combining HBV genotyping in the HBsAg region and detection of drug resistance mutations in the YMDD motif. Genotypes are indicated from A to F. The design of the strip is shown to the right, with the numbers of the probes corresponding to the numbers in Table 1 and in Figure 4. The genotypes and mutant motifs to which each probe hybridizes are written to the outer right. The combination of reactive probes allows the determination of a
20 unique genotype.

Figure 6: Example of the determination of preCore mutations by the LiPA technique. The design of the strip is shown to the right, with the numbers of the probes corresponding to the numbers in Table 1. The mutant target sequences to which the probes hybridize are indicated to the outer right. Motif M2 corresponds to a mutation in codon 28, M4 corresponds to a mutation in codon 29. M2/M4
25 has mutations in both 28 and 29.

Figure 7: Detection of a mutation in the YMDD motif of HBV pol upon treatment

with lamivudine. The graph shows a time course of the viral load during lamivudine treatment. To the right LiPA strips are shown, corresponding to assays at the beginning of the treatment (5/95), 10 months of treatment (2/96) and 14 months of treatment (6/96). The assay shows that during treatment the YMDD motif mutates to YVDD.

5

10

15

Table 1: Overview of all primers and probes referred to in the Figures with an indication of their respective SEQ ID NO and the region of the HBV genome they are designed for. Primers from the PreS1 region include 1, 106, 2 (sense primers) and 4, 107 and 3 (antisense primers). Primers from the HBsAg region include 75 and 104 (sense primers) and 76, 94 and 105 (antisense primers). Primers from the PreCore region include 5, 6, 69, 70, 84, 86, 87 and 108 (sense primers) and 7, 8, 85 and 109 (antisense primers). The remaining oligonucleotides are probes from the PreCore, PreS1, HBsAg and RT pol gene regions of HBV as indicated. The YMDDV motif and its mutants consist of amino acids 551 to 555 of the RT pol protein; the sequence MGVGL and its mutant consist of amino acids 519 to 523 of the RT pol protein; the sequence SPFLL and its mutants and genotypic variants consist of amino acids 524 to 528 of the RT pol protein.

Table 1 : HBV probe and primer design

Name	Sequence	SEQ ID NO	Region
HBPr1	GGGTCAACATATTCTTGGG	1	preS1 primer sense
HBPr2	GAACANGAGCTACNGATGG	2	preS1 primer sense
HBPr3	CCACTGATAGCCTGAGGATG	3	preS1 primer anti-sense
HBPr4	GTTCCCT/GGAACTGGAGCCNCAG	4	preS1 primer anti-sense
HBPr5	TCTTGTATTAGAGGCTGTTG	5	preCore primer sense
HBPr6	GCTTAGGCATATTGGCTTG	6	preCore primer sense
HBPr7	CTCCACGT/ANACTCANTTC	7	preCore primer anti-sense
HBPr8	GAAGGAAGAGTCAGAAGGC	8	preCore primer anti-sense
HBPr9	TGGCTTGGGGCATGG	9	preCore
HBPr10	TGGCTTGGGGCTGG	10	preCore
HBPr11	TGGCTTGGGACATGG	11	preCore
HBPr12	AAGTTGGATGGTGTG	12	preCore
HBPr13	CACCTGCGCTAATCAT	13	preCore
HBPr14	TGGGGTGGAGCCCTCNG	14	preS1
HBPr15	GCCAGCAGCCAGCCAG	15	preS1
HBPr16	CCCATGGGGACTGT	16	preS1
HBPr17	AACCCCMACAGGGATG	17	preS1
HBPr18	TCCACCACTGATCTCTT	18	preS1
HBPr19	TGGGGGAGAAATTTT	19	preS1
HBPr20	AAATTCCAGCAGTCCC	20	preS1
HBPr21	GTTCCTAACCTCTGG	21	preS1
HBPr22	AACCTCGAAMGGCAT	22	preS1
HBPr23	TGCATTCMANGGCCAC	23	preS1
HBPr24	TACTCAGCAGCTGTGCC	24	preS1
HBPr25	ACCTGGGTTGGAGGC	25	preS1
HBPr26	CNGGAAGACAGCCTAC	26	preS1
HBPr27	GATCCAGCCTTCAGAG	27	preS1
HBPr28	ATGCTCAGCTCTCAC	28	preS1
HBPr29	GCTTCTTGGAGGGTC	29	preS1
HBPr30	CTNCCCCATCTCTCC	30	preS1
HBPr31	AGCACCTCTCTCAGG	31	preS1
HBPr32	CCATGGCAGAACAGG	32	preS1
HBPr33	CTGGGGGCTCCACCCCA	33	preS1
HBPr34	ATGCACCTTTTCACCC	34	preCore
HBPr35	ATCTCTTGTACAGTGC	35	preCore

HBPr36	ATCTCATGTTCATGTGC	36	preCore
HBPr37	CAGTGGGACATGTnCA	37	preCore
HBPr38	CGTAGGACATGnCA	38	preCore
HBPr39	CTTTCAAGCTCCnA	39	preCore
HBPr40	AGCTTCAGCTGTGC	40	preCore
HBPr41	AAAGCACCnANGCA	41	preCore
HBPr42	TGGTTTAGACATGGA	42	preCore
HBPr43	GACATGACAGAGATA	43	preCore
HBPr44	GACnTGACATGAGATA	44	preCore
HBPr45	TETACNCTGCCnCTTT	45	preCore
HBPr46	TGTTCTGCTCTACTGTT	46	preCore
HBPr47	ACTGTTCAAGCCTCCAG	47	preCore
HBPr48	GGCACAGGCTGGGGCTT	48	preCore
HBPr49	ANAGCCACCCnAGGCnCA	49	preCore
HBPr50	CCRGAGGGTTGGGAAC	50	preS1
HBPr51	CAGCATGGGCFAGnATCT	51	preS1
HBPr52	TCCACCGGCHATCCTCTG	52	preS1
HBPr53	GGATCAGCTTCAGnGC	53	preS1
HBPr54	TCAGGAGAGnCCTnAC	54	preS1
HBPr55	TICACCCCnACAGGATC	55	preS1
HBPr56	ATGCTCCAGCTCCnAC	56	preS1
HBPr57	CTGCATTCAAGCCnACT	57	preS1
HBPr58	CCCCATGGGGACTGTG	58	preS1
HBPr59	CATACTACACnCTGACCA	59	preS1
HBPr60	GGCTTCTTGGnCGCTTC	60	preS1
HBPr61	CTCTCGAAAGGGGnGA	61	preS1
HBPr62	CCTACCCCnCTnCTCCn	62	preS1
HBPr63	AGCACCTCTCnCCnACnL	63	preS1
HBPr64	GCnATTCCnAGCTCCG	64	preS1
HBPr65	GCCnATGGnACnAGnTA	65	preS1
HBPr66	GACnTGACATGAGATG	66	preCore
HBPr67	GGACATGnACnAGnAT	67	preCore
HBPr68	GACATGACnAGnATG	68	preCore primer sense
HBPr69	ACATAAGGAGnCTCTGnAC	69	preCore primer sense
HBPr70	TACTCAAGACTGTGTTTA	70	preCore primer sense
HBPr71	ACnAAGACCTTnACnTCT	71	preCore promoter
HBPr72	TTCCACAGCnATCCnT	72	preCore promoter
HBPr73	GATCCnAGCTTnGnGC	73	preS1
HBPr74		74	preS1

HBPr75	CNAGGTATGGCCGGTTTGTC	HBsg primer sense	75
HBPr76	CCNNACATGGGGGAAAGCCC	HBsg primer anti-sense	76
HBPr77	CTACGGATGGAAATTGC	HBsg codon 145 wild type	77
HBPr78	TACGGACCGAAACTSC	HBsg codon 145 wild type	78
HBPr79	TTCGGACGGAAACTSC	HBsg codon 145 wild type	79
HBPr80	CTCGGACGGAAATTGC	HBsg codon 145 wild type	80
HBPr81	CTACGGATGGAAATTGC	HBsg codon 145 mutant	81
HBPr82	CTTCGGACGCAAAATTGC	HBsg codon 145 mutant	82
HBPr83	CTATGGGAGTGGGCCCTCTGT/CC	HB Pol	83
HBPr84	GCTGTAGGCTATTAATTGGCTG	preCore primer sense	84
HBPr85	CTCCACATTTAAGCTCAAATTTC	preCore primer anti-sense	85
HBPr86	ACATANGAGGAACTCTGGAC	preCore primer sense	86
HBPr87	TACTTCMANGAGCTGTGTTTA	preCore promoter	87
HBPr88	TAGGTTAAAGGTCTTTGT	preCore promoter	88
HBPr89	TAGGTAAATGATCTTGT	preCore	89
HBPr90	CATGTCCTCACTGTTCAA	preCore	90
HBPr91	CATGTCCTCACTGTTCAA	preS1	91
HBPr92	TTCTGGCCCATGCTGTA	preS1	92
HBPr93	TTCTGGCCCATGCTGTA	HBsg primer anti-sense	93
HBPr94	GGTM/TAAAGGBCATCAG/AGATG	HB Pol	94
HBPr95	TCACTATATGGATGAT	HB Pol	95
HBPr96	CAGCTATATGGATGAT	HB Pol	96
HBPr97	TTCAGCTATATGGATGAT	HB Pol	97
HBPr98	TCAGTTTATGGATGAT	HB Pol	98
HBPr99	TTTCAGTTTATGGATGAT	HB Pol	99
HBPr100	TTTAGTTTATGGATGAT	HB Pol	100
HBPr101	TCAGCTATGTGGATGAT	HB Pol	101
HBPr102	TCAGTTTATGTGGATGAT	HB Pol	102
HBPr103	TTTCAGCTATGTGGATGAT	HB Pol	103
HBPr104	CNAGGTATGGCCGGTTTGTC	HBsg primer anti-sense	104
HBPr105	GGT/CAG/TAAGGGACTCAC/AGATG	preS1 primer sense	105
HBPr106	GGGTCACTATTCCTGGG	preS1 primer anti-sense	106
HBPr107	GTTCCT/GGAATGGAGCCACAG	preCore primer sense	107
HBPr108	CGGAAAAGCTTGGCTCTTCCTTCACCTCTGGCTTC	preCore primer anti-sense	108
HBPr109	CCGGAAGCTTGGCTCTTCMAMGTTGCTATGGCTGG	preX primer sense	109
HBPr110	CCTCTGCCATTCACATGGGAAC	HB Core primer anti-sense	110
HBPr111	CTGGCAGGGGGGGGGGAGTTCTTC	HBsg primer sense	111
HBPr112	TGCCATTGTTGCTAGCTGGTCTGGAGGC	HBX primer antisense	112
HBPr113	CCGGCAGATGAGGAGGACAGACGG	HBX primer antisense	113

HbPr114	TTCAGCTATTTGGATGAT	114	YMDD motif
HbPr115	TCAGCTATTTGGATGAT	115	YMDD motif
HbPr116	TTCTAGCTATTTGGATGAT	116	YMDD motif
HbPr117	TCTAGCTATTTGGATGAT	117	YMDD motif
HbPr118	GGCTTGGGGCATGG	118	preCore codon 28 wild type
HbPr119	TGGCTTGGGGCATGG	119	preCore codon 28 wild type
HbPr120	GTCGGCTTGGGGCATGG	120	preCore codon 28 wild type
HbPr121	GGCTTGGGGCATGG	121	preCore codon 28 wild type
HbPr122	TGGCTTGGGGACATGG	122	preCore codon 28 wild type.
HbPr123	GGCTTGGGGACATGG	123	preCore codon 28 wild type.
HbPr124	TGGCTTGGGGACATGG	124	preCore codon 28 wild type.
HbPr125	GGGGCTTGGGGACATGG	125	preCore codon 28 wild type.
HbPr126	GGCTTGGGGACATGG	126	preCore codon 28 wild type.
HbPr127	TCACTTATATGGATGAT	127	YMDD genotype D, wild type
HbPr128	TTCAGTTATATGGATGAT	128	YMDD genotype D, wild type
HbPr129	TTTCAGTTATATGGATGAT	129	YMDD genotype D, wild type
HbPr130	TCACTTATGGGGATGAT	130	YMDD genotype D, mutant
HbPr131	TTCAGTTATGGGGATGAT	131	YMDD genotype D, mutant
HbPr132	TTTCAGTTATGGGGATGAT	132	YMDD genotype D, mutant
HbPr133	TTTCAGTTATGGGGATGAT	133	YMDD genotype D, mutant
HbPr134	TGCTGCTATGGCTCTCTC	134	outer HBsAg primer sense
HbPr135	CA (G/A) AGACAAAAGAAATTGG	135	outer HBsAg primer anti-sense
HbPr136	CATATGGATGGAATTTC	136	HBsAg mutant codon 143
HbPr137	CCTATGGATGGAATTTC	137	HBsAg mutant codon 143
HbPr138	ACCTATGGATGGAATTTC	138	HBsAg mutant codon 143
HbPr139	CT CAA GGC AAC TCT ATG TGG	139	HBsAg, genotype A
HbPr140	CT CAA GGC AAC TCT ATG GG	140	HBsAg, genotype A
HbPr141	T CAA GGC AAC TCT ATG TTG	141	HBsAg, genotype A
HbPr142	ATC CCA TCA TCT TGG G	142	HBsAg, genotype B
HbPr143	ATC CCA TCA TCT TGG GCG G	143	HBsAg, genotype B
HbPr144	TC CCA TCA TCT TGG GCG G	144	HBsAg, genotype B
HbPr145	C CCA TCA TCT TGG GCT GG	145	HBsAg, genotype B
HbPr146	TTC GCA AAA TAC CTA TGG	146	HBsAg, genotype B
HbPr147	T TTC GCA AAA TAC CTA TG	147	HBsAg, genotype B
HbPr148	CT TTC GCA AAA TAC CTA TG	148	HBsAg, genotype B
HbPr149	TC GCA AAA TAC CTA TGG G	149	HBsAg, genotype B
HbPr150	T CTA CCTTCCA GGA ACA T	150	HBsAg, genotype C
HbPr151	T CTA CCTTCCA GGA ACA TC	151	HBsAg, genotype C
HbPr152	CT CTA CCTTCCA GGA ACA T	152	HBsAg, genotype C

HBPr153	CT CTA CTT CCA GGA ACA G	153	HBsAg, genotype C
HBPr154	C TGC ACG ATT CCT GCT	154	HBsAg, genotype C
HBPr155	TGC ACG ATT CCT GCT CA	155	HBsAg, genotype C
HBPr156	C TGC ACG ATT CCT GCT C	156	HBsAg, genotype C
HBPr157	TGC ACG ATT CCT GCT CMA	157	HBsAg, genotype C
HBPr158	TTC GCA AGA TTC CTA TG	158	HBsAg, genotype C
HBPr159	CT TTC GCA AGA TTC CTA T	159	HBsAg, genotype C
HBPr160	CT TTC GCA AGA TTC CTA	160	HBsAg, genotype C
HBPr161	CT TCC GCA AGA TTC CTA TG	161	HBsAg, genotype C
HBPr162	C TCT ATG TAT CCC TCC T	162	HBsAg, genotype D
HBPr163	TCT ATG TAT CCC TCC TG	163	HBsAg, genotype D
HBPr164	C TCT ATG TAT CCC TCC TGG	164	HBsAg, genotype D
HBPr165	CC TCT ATG TAT CCC TCC T	165	HBsAg, genotype D
HBPr166	C TGT ACC AAA CCT TCG G	166	HBsAg, genotype D
HBPr167	C TGT ACC AAA CCT TCG	167	HBsAg, genotype D
HBPr168	GC TGT ACC AAA CCT TCG G	168	HBsAg, genotype D
HBPr169	TGT ACC AAA CCT TCG GAG	169	HBsAg, genotype D
HBPr170	GGA CCC TGC CGA ACC T	170	HBsAg, genotype E
HBPr171	GGA CCC TGC CGA ACC G	171	HBsAg, genotype E
HBPr172	G GGA CCC TGC CGA AC	172	HBsAg, genotype E
HBPr173	GGA CCC TGC CGA AC	173	HBsAg, genotype E
HBPr174	GT TGC TGT TCA AAA CCT T	174	HBsAg, genotype E
HBPr175	GT TGC TGT TCA AAA CCT G	175	HBsAg, genotype E
HBPr176	TGT TGC TGT TCA AAA CCT G	176	HBsAg, genotype E
HBPr177	A TGT TGC TGT TCA AAA CCT G	177	HBsAg, genotype E
HBPr178	GA TCC AGC ACC AGC A	178	HBsAg, genotype F
HBPr179	GGA TCC AGC ACC ACC A	179	HBsAg, genotype F
HBPr180	GGN TCC AGC ACC ACC	180	HBsAg, genotype F
HBPr181	GA TCC AGC ACC AGC AGG	181	HBsAg, genotype F
HBPr182	TGT TCC AAA CCC TCG G	182	HBsAg, genotype F
HBPr183	C TGT TCC AAA CCC TCG	183	HBsAg, genotype F
HBPr184	C TGT TCC AAA CCC TCG G	184	HBsAg, genotype F
HBPr185	GT TCC AAA CCC TCG GAT	185	HBsAg, genotype F
HBPr186	G CCA AAT CTG TGC AGC	186	HBsAg, genotype F
HBPr187	CCA AAT CTG TGC AGC AT	187	HBsAg, genotype F
HBPr188	G CCA AAT CTG TGC AGC AG	188	HBsAg, genotype F
HBPr189	GG CCA AAT CTG TGC AGC	189	HBsAg, genotype F
HBPr190	A TCA AGA AGC ACC AGT A	190	HBsAg, genotype A
HBPr191	GA TCA AGA AGC ACC AGT	191	HBsAg, genotype A

HBPr192	GA TCA ACG ACA AGC AGT \wedge	HBSAg, genotype A	192
HBPr193	GGG TCA ACG ACA ACC AGT	HBSAg, genotype A	193
HBPr194	T CAA GGC AAC TCT ATG TGG	HBSAg, genotype A	194
HBPr195	AGG TTA AAG GTC TTT GT	promoter genotype A wild type	195
HBPr196	T AGG TTA AAG GTC TTT GG	promoter genotype A wild type	196
HBPr197	TT AGG TTA AAG GTC TTT	promoter genotype A wild type	197
HBPr198	GG TTA AAG GTC TTT GTA GG	promoter genotype A wild type	198
HBPr199	AGG TTA ATG ATC ATC TTT GT	promoter genotype A mutant	199
HBPr200	T AGG TTA ATG ATC ATC TTT GG	promoter genotype A mutant	200
HBPr201	CT TTC GCA AGA TTC CTA TGG	HBSAg genotype C codon 160	201
HBPr202	GCT TTC GCA AGA TTC CTA TG	HBSAg genotype C codon 160	202
HBPr203	GCT TTC GCA AGA TTC CTA TGG	HBSAg genotype C codon 160	203
HBPr204	CT TTC GCA AGA TTC CTA TGG G	HBSAg genotype C codon 160	204
HBPr205	CC TGT ACC AAA CCT TCG GAG	HBSAg genotype C codon 160	205
HBPr206	TGC TGT ACC AAA CCT TCG G	HBSAg genotype D codon 140	206
HBPr207	TGC TGT ACC AAA CCT TCG GAG	HBSAg genotype D codon 140	207
HBPr208	GC TGT ACC AAA CCT TCG GAT	HBSAg genotype D codon 140	208
HBPr209	TGG TTC GCC GGG CTT T	HBSAg genotype D codon 140	209
HBPr210	G TGG TTC GCC GGG CTT G	HBSAg genotype E codon 184	210
HBPr211	GG TTC GCC GGG CTT TC	HBSAg genotype E codon 184	211
HBPr212	TGG TTC GCC GGG CTT TC	HBSAg genotype E codon 184	212
HBPr213	AG TGG TTC GCC GGG CTG G	HBSAg genotype E codon 184	213
HBPr214	A GGA TCC ACG ACC ACC AGG	HBSAg genotype E codon 184	214
HBPr215	\wedge GGA TCC ATG ACC ACC AGT	HBSAg genotype F	215
HBPr216	CA GGA TCC ATG ACC ACC AGG	HBSAg genotype F	216
HBPr217	C TGT TCC AAA CCC TCG GAG	HBSAg genotype F	217
HBPr218	C TGT TCC AAA CCC TCG GAT	HBSAg genotype F	218
HBPr219	GC TGT TCC AAA CCC TCG GAG	HBSAg genotype F	219
HBPr220	CTGAACTCTTACCCCGTTGC	enhancer primer	220
HBPr221	CTGCCCAACTTACAGGCCCTTC	enhancer primer	221
HBPr222	AGATGGCTTGCTGAGTC	Core primer anti-sense	222
HBPr223	GCT TTC GCA AGA TTC CTA TGG G	HBSAg genotype C codon 160	223
HBPr224	G GCT TTC GCA AGA TTC CTA TGG	HBSAg genotype C codon 160	224
HBPr225	G GCT TTC GCA AGA TTC CTA TGG C	HBSAg genotype C codon 160	225
HBPr226	G GCT TTC GCA AGA TTC CTA TGG CA	HBSAg genotype C codon 160	226
HBPr227	C AGC TAT ATG GAT GAT GTG	YMDDV motif	227
HBPr228	AGC TAT ATG GAT GAT GTG GG	YMDDV motif	228
HBPr229	GC TAT ATG GAT GAT GTG GT	YMDDV motif	229
HBPr230	AGC TAT ATG GAT GAT GTG GT	YMDDV motif	230

HBPr231	C AGC TAT ATG GAT GAT ATA		
HBPr232	AGC TAT ATG GAT GAT ATA GG		
HBPr233	GC TAT ATG GAT GAT ATA GT		
HBPr234	AGC TAT ATG GAT GAT ATA GT		
HBPr235	CCA TCA TCT TGG GCT TG		
HBPr236	CA TCA TCT TGG GCT TT	231 YMDDI MOTIF	232 YMDDI MOTIF
HBPr237	CCA TCA TCT TGG GCT TT	233 YMDDI MOTIF	233 YMDDI MOTIF
HBPr238	CCA TCA TCT TGG GCT TTC	234 YMDDI MOTIF	234 YMDDI MOTIF
HBPr239	CCC ACT GTC TGG CTT TC	235 HBSAG GENOTYPE B CODON 155	235 HBSAG GENOTYPE B CODON 155
HBPr240	CC ACT GTC TGG CTT TC	236 HBSAG GENOTYPE B CODON 155	236 HBSAG GENOTYPE B CODON 155
HBPr241	CC ACT GTC TGG CTT T	237 HBSAG GENOTYPE B CODON 155	237 HBSAG GENOTYPE B CODON 155
HBPr242	CCC ACT GTC TGG CTT G	238 HBSAG GENOTYPE B CODON 155	238 HBSAG GENOTYPE B CODON 155
HBPr243	TAT ATG GAT GAT GTC GTC	239 HBSAG GENOTYPE B CODON 190	239 HBSAG GENOTYPE B CODON 190
HBPr244	TAT GTG GAT GAT GTG GTA	240 HBSAG GENOTYPE B CODON 190	240 HBSAG GENOTYPE B CODON 190
HBPr245	TAT ATA GAT GAT GTG GTA	241 HBSAG GENOTYPE B CODON 190	241 HBSAG GENOTYPE B CODON 190
HBPr246	TAT ATT GAT GAT GTG GTA	242 HBSAG GENOTYPE B CODON 190	242 HBSAG GENOTYPE B CODON 190
HBPr247	TAT GTA GAT GAT GTG GTA	243 YMDDV MOTIF	243 YMDDV MOTIF
HBPr248	TAT GTT GAT GAT GTG GTA	244 YVDDV MOTIF	244 YVDDV MOTIF
HBPr249	TAT ATG GAT GAT ATA GTA	245 YIDDV MOTIF	245 YIDDV MOTIF
HBPr250	TAT ATG GAT GAT ATC GTA	246 YIDDV MOTIF	246 YIDDV MOTIF
HBPr251	TAT GTG GAT GAT ATA GTA	247 YVDDV MOTIF	247 YVDDV MOTIF
HBPr252	TAT GTG GAT GAT ATC GTA	248 YVDDV MOTIF	248 YVDDV MOTIF
HBPr253	TAT ATA GAT GAT ATA GTA	249 YMDDI MOTIF	249 YMDDI MOTIF
HBPr254	TAT ATA GAT GAT ATC GTA	250 YMDDI MOTIF	250 YMDDI MOTIF
HBPr255	TAT ATT GAT GAT ATA GTA	251 YVDDI MOTIF	251 YVDDI MOTIF
HBPr256	TAT ATT GAT GAT ATC GTA	252 YVDDI MOTIF	252 YVDDI MOTIF
HBPr257	TAT GTA GAT GAT ATA GTA	253 YIDDI MOTIF	253 YIDDI MOTIF
HBPr258	TAT GTA GAT GAT ATC GTA	254 YIDDI MOTIF	254 YIDDI MOTIF
HBPr259	TAT GTT GAT GAT ATA GTA	255 YVDDI MOTIF	255 YVDDI MOTIF
HBPr260	TAT GTT GAT GAT ATC GTA	256 YVDDI MOTIF	256 YVDDI MOTIF
HBPr261	TAT ATG GAT GAT CTG GTA	257 YVDDI MOTIF	257 YVDDI MOTIF
HBPr262	TAT GTG GAT GAT CTG GTA	258 YVDDI MOTIF	258 YVDDI MOTIF
HBPr263	TAT ATA GAT GAT CTG GTA	259 YVDDI MOTIF	259 YVDDI MOTIF
HBPr264	TAT ATT GAT GAT CTG GTA	260 YVDDI MOTIF	260 YVDDI MOTIF
HBPr265	TAT GTA GAT GAT CTG GTA	261 YMDDL MOTIF	261 YMDDL MOTIF
HBPr266	TAT GTT GAT GAT CTG GTA	262 YVDDL MOTIF	262 YVDDL MOTIF
HBPr267	T ATG GGA GTG GGC CTC AG	263 YIDDL MOTIF	263 YIDDL MOTIF
HBPr268	T ATG GGA TTG GGC CTC AG	264 YIDDL MOTIF	264 YIDDL MOTIF
HBPr269	C AGT CGG TTT CTC TGG GC	265 YVDDL MOTIF	265 YVDDL MOTIF
		266 YVDDL MOTIF	266 YVDDL MOTIF
		267 MGVLGL	267 MGVLGL
		268 MGVLGL	268 MGVLGL
		269 SPFLL	269 SPFLL

EXAMPLES

Example 1. HBV DNA preparation and PCR amplification

Serum samples were collected from HBsAg-positive individuals and stored at minus 20°C until use in 0.5 ml aliquots. To prepare the viral genome, 18 µl serum was
5 mixed with 2 µl 1N NaOH and incubated at 37°C for 60 minutes. The denaturation was stopped and neutralized by adding 20 µl of 0.1N HCl. After a 15 minutes centrifugation step, the supernatant was collected and the pellet discarded. PCR was carried out on this lysate as follows: 32 µl H₂O was mixed with 5 µl of 10x PCR buffer, 1 µl 10 mM dXTPs, 1 µl of each biotinylated primer (10 pmol/µl), 10
10 µl of serum lysate, and 2 U Taq enzyme. The amplification scheme contained 40 cycles of 95°C 1 min, annealing at 45°C for 1 min, and extension at 72°C for 1 min. Amplification products were visualized on 3% agarose gel.

The outer primer set for preS1 has the following sequence:

outer sense: HBPr 1: 5'-bio-GGGTCACCATATTCTTGGG- 3'

15 outer antisense HBPr 4: 5'-bio-GTTCC(T/G)GAAGTGGAGGCCACCAG-3'

The outer primer set for preCore has the following sequence:

outer sense: HBPr 69: 5'-bio-ACATAAGAGGACTCTTGGAC-3'

outer antisense: HBPr 8: 5'-bio-GAAGGAAAGAACAGAAGGC-3'

The outer primer set for HBsAg has the following sequence:

20 outer sense: HBPr 134: 5'-bio-TGCTGCTATGCCTCATCTTC-3'

outer antisense: HBPr 135: 5'-bio-CA(G/A)AGACAAAAGAAAATTGG-3'.

Samples that were negative in the first round PCR were retested in a nested reaction composed of the following: µl H₂O, 5 µl 10x Taq buffer, 1 µl 10 mM dXTPs, 1 µl of each nested primer (10 pmol/µl), 1 µl of the first round PCR product,

25 and 2 U Taq polymerase. The amplification scheme was identical as for the first round PCR. The sequence of the nested primers were as follows, for the preS1 region:

nested sense HBPr 2: 5'-bio-GAACAAAGAGCTACAGCATGGG- 3'

nested antisense HBPr 3: 5'-bio-CCACTGCATGGCCTGAGGATG-3';

and for the preCore region:

nested sense HBPr 70: 5'-bio-TACTTCAAAGACTGTGTGTTA-3'

nested antisense HBPr 7: 5'-bio- CTCCACAG(T/A)AGCTCCAAATTC-3'

In a second reaction the HBsAg region can be amplified in a similar protocol by

5 using the following primers: HBPr 75: 5'-bio-CAAGGTATGTTGCCCGTTGTCC-3'

in combination with either HBPr 76: 5'-bio-CCAAACAGTGGGGAAAGCCC-3'; or

with HBPr 94: 5'-bio-GGTA(A/T)AAAGGGACTCA(C/A)GATG-3'.

Example 2. Preparation of the Line Probe Assays

Probes were designed to cover the universal, genotypic and mutant motifs.

10 In principle only probes that discriminate between one single nucleotide variation were retained. However, for certain polymorphisms at the extreme ends of the probe, cross-reactivity was tolerated. Specificity was reached experimentally for each probe individually after considering the % (G + C), the probe length, the final concentration, and hybridization temperature. Optimized probes were provided enzymatically with a poly-T-tail using the TdT (Pharmacia) in a standard reaction condition. Briefly, 400 pmol probe was incubated at 37°C in a 30 µl reaction mix containing 5.3 mM dTTP, 25 mM Tris.HCl pH 7.5, 0.1 M sodium cacodylate, 1 mM CoCl₂, 0.1 M DTT and 170 U terminal deoxynucleotidyl transferase (Pharmacia). After one hour incubation, the reaction was stopped and the tailed probes were precipitated and washed with ice-cold ethanol. Probes were dissolved in 6x SSC at their respectively specific concentrations and applied as horizontal lines on membrane strips in concentrations between 0.2 and 2.5 pM/ml. Biotinylated DNA was applied alongside as positive control (LiPA line 1). The oligonucleotides were fixed to the membrane by baking at 80°C for 12 hours. The 15 membrane was than sliced into 4 mm strips. The design of this strip is indicated 20 probes were precipitated and washed with ice-cold ethanol. Probes were dissolved in 6x SSC at their respectively specific concentrations and applied as horizontal lines on membrane strips in concentrations between 0.2 and 2.5 pM/ml. Biotinylated DNA was applied alongside as positive control (LiPA line 1). The 25 membrane was than sliced into 4 mm strips. The design of this strip is indicated in Figure 2.

Example 3. LiPA test performance

Equal volumes (10 µl each) of the biotinylated PCR fragment and of the denaturation solution (DS; 400 mM NaOH/10 mM EDTA) were mixed in test

troughs and incubated at room temperature for 5 minutes. Then, 2 ml of the 37°C prewarmed hybridization solution (HS, 3x SSC/0.1% SDS) was added, followed by the addition of one strip per test trough. Hybridisation occurred for 1 hour at 50 ± 0.5°C in a closed shaking water bath. The strips were washed twice with 2 ml of 5 stringent wash solution (3x SSC/0.1% SDS) at room temperature for 20 seconds, and once at 50°C for 30 minutes. Following this stringent wash, strips were rinsed two times with 2 ml of the Innogenetics standard Rinse Solution (RS). Strips were 10 incubated on a rotating platform with the alkaline phosphatase-labelled streptavidin conjugate, diluted in standard Conjugate Solution for 30 minutes at room temperature (20 to 25°C). Strips were then washed twice with 2 ml of RS and once with standard Substrate Buffer (SB), and the colour reaction was started by adding BCIP and NBT to the SB. After maximum 30 minutes at room temperature, the colour reaction was stopped by replacing the colour compounds by distilled 15 water. Immediately after drying, the strips were interpreted. Reactivities were considered positive whenever the reactivity was stronger than the reaction on the negative control. Strips can be stored on a dry dark place. The complete procedure described above can also be replaced by the standardized Inno-LiPA automation device (auto-LiPA).

Example 4. Selection of reference material.

20 PCR fragments were prepared, derived from members of the different genotypes, the different preCore wild type and mutant sequences, drug resistant motifs and vaccine escape mutants. The PCR fragments were amplified with primers lacking the biotine group at their 5'-end and cloned into the pretreated EcoRV site of the pGEMT vector (Promega). Recombinant clones were selected 25 after α-complementation and restriction fragment length analysis, and sequenced with plasmid primers. Other biotinylated fragments were directly sequenced with a dye-terminator protocol (Applied Biosystems) using the amplification primers. Alternatively, nested PCR was carried out with analogs of the primers, in which the biotine group was replaced with the T7- and SP6-primer sequence, respectively. 30 These amplicons were then sequenced with an SP6- and T7-dye-primer procedure.

By doing so, a reference panel of recombinant clones was prepared, which is necessary for optimizing LiPA probes.

Example 5: Genotyping HBV-infected serum samples.

Only after creating a sequence alignment as shown in Figure 1, it became clear which regions could be useful for HBV genotyping. The preS1 region seems to be suitable because of the high degree of variability. Probes were therefore designed to cover most of these variable regions as shown in Table 1. Only a limited selection of probes was retained because of their specific reaction with the reference panel. The most important ones are indicated as boxed regions in Figure 1. These selected probes were then applied in a LiPA format indicated in Figure 2, as line number 2 to 14. Some of the probes could be applied together in one line, because of their universal character, while others need to be applied separately. With the selection of probes thus obtained, serum samples collected in different parts of the world (Europe, South-America, Africa, Middle-East) were tested. The upper part of Figure 3 shows the reactivity of a selection of samples on these probes. Genotyping of these samples is straightforward, with samples 2 to 8 belonging to genotype A, samples 9 and 10 belonging to genotype B, samples 11 and 12 belonging to genotype C, samples 13 to 19 belonging to genotype D, samples 20 to 23 belonging to genotype E, and sample 24 belonging to genotype F.

Genotyping can also be performed in the HBsAg region. Again, probes were designed to cover most of the variable regions shown in Fig. 1. Only a limited selection of probes were retained. These probes are boxed in Fig. 1 and are listed in Figure 4. A LiPA strip was prepared carrying these probes and samples belonging to the different genotypes were characterized, as shown in Fig. 5.

Example 6. Scanning the preCore region for mutations.

HBeAg expression can be regulated at the transcriptional and translational level. It is postulated that a transcriptional regulation exists due to the presence of a dinucleotide variation in the promoter region of the preCore mRNA. Probes

covering the wild type (e.g. probe HBPr 88) and the mutant (e.g. HBPr 89) motif were selected and their positions are indicated in the alignment shown in Figure 1, and applied on the LiPA strip as line 15 and 16 (Figure 2).

At the translational level, much more mutations might arise, all possibly resulting in abrogation of the HBeAg expression: any mutations at codon 1 (ATG) destroying translation initiation, codon 2 (CAA to TAA), codon 7 (TGC to TGA), codon 12 (TGT to TGA), codon 13 in genotype B, C, D, E, F (TCA to TGA or TAA), codon 14 (TGT to TGA), codon 18 (CAA to TAA), codon 21 (AAG to TAG), codon 23 (TGC to TGA), codon 26 (TGG to TAG or TGA), codon 28 (TGG to TAG or TGA).

However, due to secondary constrain of the encapsidation signal, most of the mutations occur at codon 28 (TGG to TAG). Along with the mutation at codon 28, a second mutation at codon 29 (GGC to GAC) is often observed. In the case of genotype A and again as a consequence of the secondary constrain, stop codon mutations at codon 28 are only likely to occur after selection of a codon 15 mutation (CCC to CCT). Hence, correct interpretation of preCore mutations is genotype dependent. In addition to the above mentioned stop codons, a huge amount of different deletion- or insertion-mutations in the preCore open reading frame might give essentially the same result.

In order to develop a sensitive assay to detect the relevant mutations and the hypothetical mutations, a probe scanning procedure was developed. Partially overlapping probes were designed and applied in a LiPA format (Figure 2, line 17 to 27). In this assay format, wild type sequences over the complete preCore region, together with the codon 15 variation for genotype A versus non-A genotypes, and the most common mutations at codon 28 (TAG), at codon 29 (GAC) and the combination of codon 28 and 29 (TAGGAC) are positively recognized. Absence of reactivity at one of the other probes is always indicative for the presence of a variation. The exact nature of this variation can then be revealed by sequence analysis or with further designed LiPA probes.

Figure 3 shows the reactivity of the selected genotyped samples on the probes for the preCore region. Samples were previously tested for the presence of HBeAg or for anti-HBe. The interpretation of the reactivity on the LiPA probes for

each sample is indicated below each strip. This approach allowed for the simultaneous screening of a sample for preCore mutations and the characterization of the viral genotype.

Figure 6 also shows a panel of samples with mutations in the preCore region, as well as wild type samples. The probes used in this assay are listed in 5 Figure 4. This assay includes a codon 29 mutant (M4 motif), which was not present in the experiment in Figure 3.

Example 7. Detection of mutants in the HBsAg region.

Vaccine escape mutants have been described. The most commonly found 10 mutant is the variation at codon 145 of HBsAg (G145R or GGA to AGA). LiPA probes are designed to detect wild type and mutant probes. Genotypic variations are present in the vicinity of codon 145. Therefore, genotype A is covered by probe 77, genotype B by probe 78, genotype C by probe 79, and genotype D/E by probe 80. Hence, in principle, it is possible to genotype and detect the wild type 15 strains of the virus in one single experiment. Mutant target sequences are covered by probe 81 and 82 for genotype A and D, respectively. Probe 83 can be used as a positive control in these experiments. Further detection of mutants in the a determinant region is possible by means of a probe scanning approach. Herefore, probes are designed to cover the wild type sequence of the different genotypes 20 over the HBsAg epitope region and applied in a LiPA format. Again here, absence of staining at one of these probes is indicative for the presence of a mutant strain. The exact nature of this variant is then determined by sequencing analysis.

Example 8. Detection of HBV strains resistant to lamivudine.

Through analogy with HIV and the resistance against the anti-viral compound 25 3TC (lamivudine or (-)-β-1-2',3'-dideoxy-3'-thiacytidine), it was predicted that upon treatment of HBV-infected patients with 3TC, viral strains would be selected showing resistance at the YMDD motif in the HB pol gene. The YMDD motif is physically located in the HBsAg region, but is encoded in another reading frame. Hence, this part of the HBV pol region is amplified with the primer combination

HBPr 74-HBr 94, but not with the combination HBPr 74-HBr 76. Probes covering the wild type YMDD motif and YVDD mutant motif are indicated in Figure 1, respectively probes 95 to 100 and 101 to 103, as well as probes 115, 116, 127 and 132, the latter probes yielding the best results in the LiPA assay. Such an assay was used to determine the presence of mutations in the YMDD motif in serum of a HBV-infected patient during treatment with lamivudine. Fig. 7 shows that in the first phase of the treatment (May 1995) no mutations were detected. During the treatment, the viral load decreased, reaching a level of approximately 10^4 during November and December 1995, whereafter a breakthrough was observed, resulting in a level as high as during the first months of the treatment by June 1996. Interestingly, a LiPA assay performed in February 1996 indicated that the majority of virus present, possessed a mutation in the YMDD motif, which had changed to YVDD. In June 1996, no more wild type motif, but only mutant YVDD could be detected. With this assay, resistant HBV strains can thus easily be detected. Furthermore, the combined detection of the YMDD motif and preCore mutants might be clinically important in prediction and prognosis of further treatment.

REFERENCES.

- Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Nucleic acid-binding molecules with high affinity and base sequence specificity : intercalating agents covalently linked to oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 81(11):3297-301.
- Barany F. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci USA 1991; 88: 189-193.
- Bej A, Mahbubani M, Miller R, Di Cesare J, Haff L, Atlas R. Multiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water. Mol Cell Probes 1990; 4:353-365.
- Boom R., Sol C.J.A., Salimans M.M.M., et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503.
- Carman W, Zanetti A, Karayannidis P, Waters J, Manzillo G, Tanzi E, Zuckerman A, and Thomas H. Vaccine induced escape mutants. Lancet 1990; 336:325-329.
- Carman W, Korula J, Wallace L, MacPhee R, Mimms L, and Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAG ELISA. Lancet 1995; 345: 1406-1407.
- Compton J. Nucleic acid sequence-based amplification. Nature 1991; 350: 91-92.
- Crawford D. Hepatitis B virus 'escape' mutants: A rare event which causes vaccination failure. British Med. J. 1990; 301: 1058-1059.
- Duck P. Probe amplifier system based on chimeric cycling oligonucleotides. Biotechniques 1990; 9: 142-147.

Gao Q, Gu Z, Parniak M, Cameron I, Cammack N, Boucher C, and Wainberg M. The same mutation that encodes low-level human immunodeficiency virus type-1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. *Antimicrob Agents Chemother.* 1993; 37: 1390-1392.

Guatelli J, Whitfield K, Kwok D, Barringer K, Richman D, Gengeras T. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. *Proc Natl Acad Sci USA* 1990; 87: 1874-1878.

Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical 10 recognition to pathogenesis and treatment. *Viral Hepatitis* 1995; 1: 7-36.

Honkoop P, de Man R, Zondervan P, Niesters H, and Schalm S. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine is associated with a decrease in HBV-DNA by PCR. *Hepatol.* 1995; 22: abstract 887.

15 Kwok D, Davis G, Whitfield K, Chappelle H, Dimichele L, Gengeras T. Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. *Proc Natl Acad Sci USA* 1989; 86: 1173-1177.

20 Kwok S, Kellogg D, McKinney N, Spasic D, Goda L, Levenson C, Sinisky J. Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies. *Nucl. Acids Res.* 1990; 18: 999.

Landgren U, Kaiser R, Sanders J, Hood L. A ligase-mediated gene detection technique. *Science* 1988; 241:1077-1080.

Li J-S, Tong S-P, Wen Y-M, Vivitski L, Zhang Q, and Trépo C. Hepatitis B virus

genotype A rarely circulates as an Hbe-minus mutant: possible contribution of a single nucleotide in the preCore region. J. Virol. 1993; 67: 5402-5410.

5 Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G.M. and Harrison, T.J. Selection of mutations in the Hepatitis B Virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713.

Lok A, Akarca U, and Greene S. Mutations in the precore region of hepatitis B virus serve to enhance of the secondary structure of the pre-genome encapsidation signal. Proc. Natl. Acad. Sci. USA 1994; 91: 4077-4081.

10 Lomeli H, Tyagi S, Printchard C, Lisardi P, Kramer F. Quantitative assays based on the use of replicatable hybridization probes. Clin Chem 1989; 35: 1826-1831.

Magnius L, and Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38: 24-34.

15 Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J, Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides : inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84(21):7706-10.

20 Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. Biochemistry 18(23):5134-43.

Naoumov N, Perillo R, Chokshi S, Dienstag J, Vicary C, Brown N, and Williams R. Reduction in hepatitis B virus quasispecies during lamivudine treatment is associated with enhanced virus replication and hepatocytolysis. Hepatol. 1995; 22: abstract 885.

- Nielsen P, Egholm M, Berg R, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science* 254(5037):1497-500.
- 5 Nielsen P, Egholm M, Berg R, Buchardt O (1993) Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. *Nucleic-Acids-Res.* 21(2):197-200.
- Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, and Mayumi M. Hepatitis B virus with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. *J. Virol.* 1990; 64: 1298-1303.
- 10 Saiki R, Walsh P, Levenson C, Erlich H. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes *Proc Natl Acad Sci USA* 1989; 86:6230-6234.
- 15 Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. *Ann. Intern. Medicine* 1995; 122: 241-248.
- Shaw, T., Mok, S.S., Locarnini, S.A. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. *Hepatology* 1996; 24: 996-1002.
- 20 Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. *J. Gen. Virol.* 1993; 74 : 1093-1102.
- Takahashi K, Aoyama K, Onhno N, Iwata K, Akahane Y, Baba K, Yoshizawa H, and Mishiro S. The precore/core promoter mutant (T1762A1764) of hepatitis B virus:

clinical significance and an easy method for detection. J. Gen. Virol. 1995; 76: 3159-3164.

5 Tipples, G.A., Ma, M.M., Fischer, K.P., Bain, V.G., Kneteman, N.M. and Tyrell, D.L.J. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717.

Waters J, Kennedy M, Voet P, Hauser P, Petre J, Carman W, and Thomas H. Loss of the common 'a' determinant of hepatitis B surface antigen by vaccine-induced escape mutants. J. Clin. Invest. 1992; 90: 2543-2547.

10 Wu D, Wallace B. The ligation amplification reaction (LAR) - amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics 1989; 4:560-569.

Yuan T, Faruqi A, Shih J, and Shih C. The mechanism of natural occurrence of two closely linked HBV precore predominant mutations. Virol. 1995; 211: 144-156.

15 Zhang X, Zoulim F, Habersetzer F, Xiong S, and Trépo C. Analysis of hepatitis B virus genotypes and preCore region variability during interferon treatment of Hbe antigen negative chronic hepatitis B. J. Med. Virol. 1996; xxx-xxx.

CLAIMS

1. Method for detection and/or genetic analysis of HBV in a biological sample, comprising:
 - 5 (i) if need be releasing, isolating or concentrating the polynucleic acids present in said sample;
 - (ii) if need be amplifying the relevant part of a suitable HBV gene present in said sample with at least one suitable primer pair;
 - (iii) hybridizing the polynucleic acids of step (i) or (ii) with a combination of at 10 least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from Figure 1, and with said probes being applied to known locations on a solid support and with said probes being capable of hybridizing to the polynucleic acids of step (i) or (ii) under the same hybridization and wash conditions, or with said probes hybridizing specifically with a sequence complementary to any of said target sequences, 15 or a sequence wherein T of said target sequence is replaced by U;
 - (iv) detecting the hybrids formed in step (iii);
 - (v) inferring the HBV genotype and/or mutants present in said sample from the differential hybridization signal(s) obtained in step (iv).
- 20
25 2. Method according to claim 1, characterized further in that in step (iii) a combination of at least two oligonucleotide probes is used and that said combination of probes hybridizes specifically to at least two of the following groups of target sequences:
a mutant target sequence chosen from the HBV RT pol gene region,
a mutant target sequence chosen from the HBV preCore region,

a mutant target sequence chosen from the HBsAg region of HBV,
a HBV genotype-specific target sequence.

3. Method according to claim 1, characterized further in that in step (iii) a combination of at least three oligonucleotide probes is used and that said combination of probes hybridizes specifically to at least three of the following groups of target sequences:

5 a mutant target sequence chosen from the HBV RT pol gene region,
a mutant target sequence chosen from the HBV preCore region,
a mutant target sequence chosen from the HBsAg region of HBV,
10 a HBV genotype-specific target sequence.

4. Method according to claim 1, characterized further in that in step (iii) a combination of at least four oligonucleotide probes is used and that said combination of probes hybridizes specifically to all of the following groups of target sequences:

15 a mutant target sequence chosen from the HBV RT pol gene region,
a mutant target sequence chosen from the HBV preCore region,
a mutant target sequence chosen from the HBsAg region of HBV,
a HBV genotype-specific target sequence.

5. Method according to any of claims 1 to 4, characterized further in that the
20 oligonucleotide probes used in step (iii) are selected from Table 1, wherein:
-the probes hybridizing specifically to mutant target sequences chosen from
the RT pol region of HBV are selected from the following list:

SEQ ID 114, SEQ ID NO 115, SEQ ID NO 116, SEQ ID NO 117, SEQ ID NO
127, SEQ ID NO 128, SEQ ID NO 129, SEQ ID NO 130, SEQ ID NO 131,
25 SEQ ID NO 132, SEQ ID NO 133, SEQ ID NO 227, SEQ ID NO 228, SEQ ID
NO 229, SEQ ID NO 230, SEQ ID NO 231, SEQ ID NO 232, SEQ ID NO
233, SEQ ID NO 234, SEQ ID NO 243, SEQ ID NO 244, SEQ ID NO 245,
SEQ ID NO 246, SEQ ID NO 247, SEQ ID NO 248, SEQ ID NO 249, SEQ ID

NO 250, SEQ ID NO 251, SEQ ID NO 252, SEQ ID NO 253, SEQ ID NO
254, SEQ ID NO 255, SEQ ID NO 256, SEQ ID NO 257, SEQ ID NO 258,
SEQ ID NO 259, SEQ ID NO 260, SEQ ID NO 261, SEQ ID NO 262, SEQ ID
NO 263, SEQ ID NO 264, SEQ ID NO 265, SEQ ID NO 266, SEQ ID NO
267, SEQ ID NO 268, SEQ ID NO 269, SEQ ID NO 270, SEQ ID NO 271,
SEQ ID NO 272, SEQ ID NO 273, SEQ ID NO 274, SEQ ID NO 275, SEQ ID
NO 276, SEQ ID NO 277, SEQ ID NO 278, and/or

5 -the probes hybridizing specifically to mutant target sequences chosen from
the preCore region of HBV are selected from the following list:

10 SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13,
SEQ ID NO 34, SEQ ID NO 35, SEQ ID NO 36, SEQ ID NO 37, SEQ ID NO
38, SEQ ID NO 39, SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID
NO 43, SEQ ID NO 44, SEQ ID NO 45, SEQ ID NO 46, SEQ ID NO 47, SEQ
15 ID NO 48, SEQ ID NO 49, SEQ ID NO 66, SEQ ID NO 67, SEQ ID NO 68,
SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 90, SEQ ID NO 91, SEQ ID NO
118, SEQ ID NO 119, SEQ ID NO 120, SEQ ID NO 121, SEQ ID NO 122,
SEQ ID NO 123, SEQ ID NO 124, SEQ ID NO 125, SEQ ID NO 126, and/or

20 -the probes hybridizing specifically to mutant target sequences chosen from
the HBsAg region of HBV are selected from the following list:

SEQ ID NO 77, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO
81, SEQ ID NO 82, SEQ ID NO 136, SEQ ID NO 137, SEQ ID NO 138,
and/or

25 -the probes hybridizing specifically to genotype-specific target sequences of
HBV are selected from the following list:

SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO
18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, SEQ ID
30 NO 23, SEQ ID NO 24, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 27, SEQ
ID NO 28, SEQ ID NO 29, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32,

SEQ ID NO 33, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 57, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 60, SEQ ID NO 61, SEQ ID NO 62, SEQ ID NO 63, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 73, SEQ ID NO 74,
5 SEQ ID NO 92, SEQ ID NO 93, SEQ ID NO 77, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 139, SEQ ID NO 140, SEQ ID NO 141, SEQ ID NO 142, SEQ ID NO 143, SEQ ID NO 144, SEQ ID NO 145, SEQ ID NO 146, SEQ ID NO 147, SEQ ID NO 148, SEQ ID NO 149, SEQ ID NO 150, SEQ ID NO 151, SEQ ID NO 152, SEQ ID NO 153, SEQ ID NO 154, SEQ ID NO 155, SEQ ID NO 156, SEQ ID NO 157, SEQ ID NO 158, SEQ ID NO 159, SEQ ID NO 160, SEQ ID NO 161, SEQ ID NO 162, SEQ ID NO 163, SEQ ID NO 164, SEQ ID NO 165, SEQ ID NO 166, SEQ ID NO 167, SEQ ID NO 168, SEQ ID NO 169, SEQ ID NO 170, SEQ ID NO 171, SEQ ID NO 172, SEQ ID NO 173, SEQ ID NO 174, 10 SEQ ID NO 175, SEQ ID NO 176, SEQ ID NO 177, SEQ ID NO 178, SEQ ID NO 179, SEQ ID NO 180, SEQ ID NO 181, SEQ ID NO 182, SEQ ID NO 183, SEQ ID NO 184, SEQ ID NO 185, SEQ ID NO 186, SEQ ID NO 187, SEQ ID NO 188, SEQ ID NO 189, SEQ ID NO 190, SEQ ID NO 191, SEQ ID NO 192, SEQ ID NO 193, SEQ ID NO 194.

- 20 6. Method according to any of claims 1 to 5, wherein the oligonucleotide probes of step (iii) are characterized in that they specifically hybridize to target sequences in the RT pol region of HBV and permit detection of mutations that confer resistance to lamivudine, with said probes being for instance SEQ ID NO 114, SEQ ID NO 115, SEQ ID NO 116, SEQ ID NO 117, 25 SEQ ID NO 127, SEQ ID NO 128, SEQ ID NO 129, SEQ ID NO 130, SEQ ID NO 131, SEQ ID NO 132, SEQ ID NO 133, SEQ ID NO 227, SEQ ID NO 228, SEQ ID NO 229, SEQ ID NO 230, SEQ ID NO 231, SEQ ID NO 232, SEQ ID NO 233, SEQ ID NO 234, SEQ ID NO 243, SEQ ID NO 244, SEQ ID NO 245, SEQ ID NO 246, SEQ ID NO 247, SEQ ID NO 248, SEQ ID NO 30 249, SEQ ID NO 250, SEQ ID NO 251, SEQ ID NO 252, SEQ ID NO 253,

SEQ ID NO 254, SEQ ID NO 255, SEQ ID NO 256, SEQ ID NO 257, SEQ ID
NO 258, SEQ ID NO 259, SEQ ID NO 260, SEQ ID NO 261, SEQ ID NO
262, SEQ ID NO 263, SEQ ID NO 264, SEQ ID NO 265, SEQ ID NO 266,
SEQ ID NO 269, SEQ ID NO 270, SEQ ID NO 271, SEQ ID NO 272, SEQ ID
5 NO 275, SEQ ID NO 276, SEQ ID NO 277, SEQ ID NO 278.

7. Method according to any of claims 1 to 5, wherein the oligonucleotide probes of step (iii) are characterized in that they specifically hybridize to target sequences in the RT pol region of HBV and permit detection of mutations that confer resistance to penciclovir, with said probes being for instance SEQ ID NO 267, SEQ ID NO 268, SEQ ID NO 269, SEQ ID NO 270,
10 SEQ ID NO 271, SEQ ID NO 272, SEQ ID NO 273, SEQ ID NO 274, SEQ ID
NO 275, SEQ ID NO 276, SEQ ID NO 277, SEQ ID NO 278.
8. Method according to any of claims 1 to 5, wherein the oligonucleotide probes of step (iii) are characterized in that they specifically hybridize to target sequences in the RT pol region of HBV and permit detection of at least one of the mutations that give rise to a change of the following amino acids: F at position 514, V at position 521, P at position 525, L at position 527, M at position 552, V at position 555, with said probes being for instance SEQ ID NO 114, SEQ ID NO 115, SEQ ID NO 116, SEQ ID NO 117,
15 SEQ ID NO 127, SEQ ID NO 128, SEQ ID NO 129, SEQ ID NO 130, SEQ ID
NO 131, SEQ ID NO 132, SEQ ID NO 133, SEQ ID NO 227, SEQ ID NO
228, SEQ ID NO 229, SEQ ID NO 230, SEQ ID NO 231, SEQ ID NO 232,
20 SEQ ID NO 233, SEQ ID NO 234, SEQ ID NO 243, SEQ ID NO 244, SEQ ID
NO 245, SEQ ID NO 246, SEQ ID NO 247, SEQ ID NO 248, SEQ ID NO
249, SEQ ID NO 250, SEQ ID NO 251, SEQ ID NO 252, SEQ ID NO 253,
25 SEQ ID NO 254, SEQ ID NO 255, SEQ ID NO 256, SEQ ID NO 257, SEQ ID
NO 258, SEQ ID NO 259, SEQ ID NO 260, SEQ ID NO 261, SEQ ID NO
262, SEQ ID NO 263, SEQ ID NO 264, SEQ ID NO 265, SEQ ID NO 266,
SEQ ID NO 267, SEQ ID NO 268, SEQ ID NO 269, SEQ ID NO 270, SEQ ID

NO 271, SEQ ID NO 272, SEQ ID NO 273, SEQ ID NO 274, SEQ ID NO
275, SEQ ID NO 276, SEQ ID NO 277, SEQ ID NO 278.

9. Method according to any of claims 1 to 5, characterized further in that the
probes of step (iii) hybridize specifically to a genotype-specific target
sequence from the HBsAg region, said probes being for instance SEQ ID NO
5 77, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO 81, SEQ ID
NO 82, SEQ ID NO 139, SEQ ID NO 140, SEQ ID NO 141, SEQ ID NO 142,
SEQ ID NO 143, SEQ ID NO 144, SEQ ID NO 145, SEQ ID NO 146, SEQ ID
NO 147, SEQ ID NO 148, SEQ ID NO 149, SEQ ID NO 150, SEQ ID NO
10 151, SEQ ID NO 152, SEQ ID NO 153, SEQ ID NO 154, SEQ ID NO 155,
SEQ ID NO 156, SEQ ID NO 157, SEQ ID NO 158, SEQ ID NO 159, SEQ ID
NO 160, SEQ ID NO 161, SEQ ID NO 162, SEQ ID NO 163, SEQ ID NO
164, SEQ ID NO 165, SEQ ID NO 166, SEQ ID NO 167, SEQ ID NO 168,
SEQ ID NO 169, SEQ ID NO 170, SEQ ID NO 171, SEQ ID NO 172, SEQ ID
15 173, SEQ ID NO 174, SEQ ID NO 175, SEQ ID NO 176, SEQ ID NO
177, SEQ ID NO 178, SEQ ID NO 179, SEQ ID NO 180, SEQ ID NO 181,
SEQ ID NO 182, SEQ ID NO 183, SEQ ID NO 184, SEQ ID NO 185, SEQ ID
NO 186, SEQ ID NO 187, SEQ ID NO 188, SEQ ID NO 189, SEQ ID NO
190, SEQ ID NO 191, SEQ ID NO 192, SEQ ID NO 193, SEQ ID NO 194,
20 195, SEQ ID NO 214, SEQ ID NO 215, SEQ ID NO 216, SEQ ID NO 217, SEQ ID
NO 218, SEQ ID NO 219.

10. Method according to any of claims 1 to 5, characterized further in that the
probes of step (iii) hybridize specifically to a genotype-specific target
sequence from the preS1 region, said probes being for instance SEQ ID NO
25 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID
NO 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, SEQ ID NO 23, SEQ
ID NO 24, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 27, SEQ ID NO 28,
SEQ ID NO 29, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO
33, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ ID NO 53, SEQ ID

NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 57, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 60, SEQ ID NO 61, SEQ ID NO 62, SEQ ID NO 63, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 73, SEQ ID NO 74, SEQ ID NO 92, SEQ ID NO 93.


- 5 11. A composition comprising at least one probe as defined in any of claims 1 to 10.
12. A composition comprising at least one probe as defined in claim 5.
13. Use of a composition of probes as defined in claims 11 and/or 12 for *in vitro* diagnosing and/or monitoring HBV mutants and/or genotypes present in a
10 biological sample.
14. Assay kit for the detection and/or the genetic analysis of HBV mutants and/or genotypes present in a biological sample according to the method of any of claims 1 to 10, comprising the following components :
15 (i) when appropriate, a means for releasing, isolating or concentrating the polynucleic acids present in said sample;
 (ii) when appropriate, at least one suitable primer pair;
 (iii) at least one of the probes according to claim 11 and/or 12, possibly fixed to a solid support;
 (iv) a hybridization buffer, or components necessary for producing said buffer;
20 (v) a wash solution, or components necessary for producing said solution;
 (vi) when appropriate, a means for detecting the hybrids resulting from the preceding hybridization.
 (vii) when appropriate, a means for attaching said probe to a known location on a solid support.

1/28

Figure 1

Start HBsAg

ACGAGACATGGAGAATCAGGAATCCAGAACATCACATCGGTCAGCTGTTGACTCTCAATTCTAGGGGGTACCCGTGTG!	A	A	C
HBVXP5	-1-		
HBVQW	..		
HVIIFB	..		
SS0225	..		
HPBAUZCG	C--	C--	C--
HPBAUJ3	C--	G--	C--
HPBAUJ2	C--	G--	C--
HPBAUJ1	C--	G--	C--
HPBAUJ2	C--	G--	C--
HPBCGJDR	C--	G--	C--
HBVAZH	C--	G--	CA--
HPBARA	C--	G--	CA--
HPBCG	C--	G--	CA--
IEIBVAYR	C--	G--	CA--
HBVADR	C--	G--	CA--
HBVABA	C--	G--	CA--
HPBAR1C	C--	G--	CA--
HPBARC	C--	G--	CA--
IBVPREX	C--	G--	CA--
IPBEINC	C--	G--	CA--
IIIVBC	..	G--	CA--
IIIVCIA	..	G--	CA--
HBVATMCG	CT-
HBVATMC	CT-
HBVATHC1	CT-
HBVATE	CT-
HBVDA	CT-
HPBIIVYAA	CT-
XXIIEPAV	CT-
UBVOFS	CT-
HBVBE4	C--	A-G-	..
IIIVBAS	C--	A-G-	..
IIIVBFF
IIIVBFOU
HBVADKA



6/28

IBP-F94		End of IBSAG
751	TCGTATGGGCCAAGACGTACAGTGAGTCCCTTATACCGTGTACCAATTCTTCTGGTCAGGTTAACCTAACAAACAAAGATGGGTTATCCCIAACTCATGGCTACATAATGGAGT	G
IBVXCP5
HBVADV
HVIEP8
S20225
HPBAD12CG	C.....
HPBAD13	T.....
HPBAD12	T.....
HPBAD91	T.....
HPBAD12	T.....
HPBCGADR	A.....
HBVADRM	A.....
HPBADRA	A.....
HPBCG	A.....
HEHBVA YR	A.....
HBVADR	A.....
HBVADR4	A.....
HPBADR1C	A.....
HPBADRC	A.....
IBPREX	A.....
HPDEINC	A.....
HHVBC	G.....
HHVCCA	G.....
HHVAYMCG	A.....
HBVATHC	A.....
HBVATUC	A.....
HBVATUE	A.....
HBVDDA	A.....
HPBIBVVA	A.....
XHIEPAV	A.....
HBVORTS	A.....
HHVBE4	GA.....
HHVBBAS	A.....
HHVBF	A.....
HHVBFQD	A.....
HBVDDA	A.....

7/28

9 / 28

10/28

11/28

12/28

12/28

165P

165P-69


165P-70

165P-71

Core promoter

preCore promoter

iPA probe



BNSCPS	HBVADW	HVHEPB	HBPF 8	CCTGGTTTCGCTCTGACATCTCCCTAGACACGCCCTAGGCTGATGCTGTAGAGCTTAGACCTAGCCTACGCAAGCCATCTGCTGGGGAAATGAT
SS0225	CA
HPBADW3	TCA	G...T-CTGACT-CI-C-I-C	TC-G-A-TCTA-TAGA-T-A
HPBADW
HPBADW2
HPBADW1
HPBADW
HPBCGADR
HBVADRM
HPBADRA
HPBCG
HBVAYR
HBVADR
HBVADRM
HPBADRC
HPBADRC
HBPREX
HPBE1NC
IIIHBC
HNVCCH
HBVATNCG
HBVATNC
HBVATIC
HBVATNE
HBVDNA
HPBIBVA
XHHEPAV
HBVORFS
IIIHBEB
IIIHBBS
HHVBFF
IIIHBFBFOU
HBVADW4

15/28

17/28

18/28

	IBPR 1									
2701	T	A	A	C	G	T	A	T	C	G
HBVCP5
HBVADW
HBVHEB
HPBADM2CG	-A-----	I-----	I-----	C-----	G-----	G-----	G-----	G-----	G-----
HPBADM3	-G-----	G-----	G-----	G-----	G-----	G-----	G-----	G-----	G-----
HPBADM2	-C-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----
HPBADM1	-C-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----
HPBADM2	-C-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----	-G-----
HPBCGDR	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVADM	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HPBADR	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HPBCG	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HEBVAYR	G-----G-----	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVADR	G-----G-----	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVADM4	A-----A-----	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HPBADIC	A-----A-----	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HPBADRC	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVPREX	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HPBE1NC	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HHVBC	A-----AC-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HINVCCA	I-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVAYMC	G-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVAYMC	A-----IC-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVAYU1	A-----IC-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVAYU2	G-----IC-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HBVOMA	A-----IC-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
HPBUIBVA	A-----IT-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
XXIEPAV	G-----A-----	I-----C-----	I-----A-----	I-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----	G-----G-----
IBVDFRS
HHVBC4	-A-----	-A-----I-----	-A-----C-----	-A-----G-----	-A-----A-----	-G-----G-----	-G-----G-----	-G-----G-----	-G-----G-----	-G-----G-----
HHVBAS	-A-----	-A-----I-----	-A-----C-----	-A-----G-----	-A-----A-----	-G-----G-----	-G-----G-----	-G-----G-----	-G-----G-----	-G-----G-----
HHVBF	-C-----	-G-----I-----C-----	-G-----I-----G-----	-G-----I-----A-----	-G-----I-----T-----A-----	-G-----G-----G-----	-G-----G-----G-----	-G-----G-----G-----	-G-----G-----G-----	-G-----G-----G-----
HHVBTOU	-C-----	-C-----I-----G-----C-----	-C-----I-----G-----A-----	-C-----I-----G-----T-----A-----	-C-----I-----G-----A-----T-----A-----	-G-----G-----G-----	-G-----G-----G-----	-G-----G-----G-----	-G-----G-----G-----	-G-----G-----G-----
HBVADWA

LIP

Pr

50

22

20/28

92

Start HBpres1ag

HBPr 2

TACAGC ATGGGGGG TGGTCAATCAANCTCCAAAGGCAATGGGAGGAICITIC	[REDACTED]	TTCGACTATAGTGACCATAGTCAGATGGACCTGGATTCAGAATCCGAACTCAACCCCCATC	CG	C	C	C	ACA
HBVXCP5	[REDACTED]	[REDACTED]	CG	CG	C	C	ACA
HBVADU	[REDACTED]	[REDACTED]	AA	AA	C	C	ACA
HWIFPR	[REDACTED]	[REDACTED]	AA	AA	G	A	ACA
S50225	-I-	-G-A	I	I	I	I	ACA
HPBADUZCG	-I-	-C-C	AC	-C-C	I	I	57
HPBADU3	-I-	-C-C	AC	-C-C	I	I	
HPBADU	-I-	-C-C	AC	-C-C	I	I	
HPBADU1	-I-	-C-C	AC	-C-C	I	I	
HPBADU2	-I-	-C-C	AC	-C-C	I	I	
HPBCGADR	-I-	-C-C	AC	-C-C	I	I	
HBVADRH	-I-	-C-C	AC	-C-C	I	I	
HPBADM	-I-	-C-C	AC	-C-C	I	I	
HPBCG	-I-	-C-C	AC	-C-C	I	I	
HEHBVAYR	-I-	-C-C	AC	-C-C	I	I	
HBVADR	-I-	-C-C	AC	-C-C	I	I	
HBVADR4	-I-	-C-C	AC	-C-C	I	I	
HPBDR1C	-I-	-C-C	AC	-C-C	I	I	
HPBDR2C	-I-	-C-C	AC	-C-C	I	I	
HBVPREX	-I-	-C-C	AC	-C-C	I	I	
HPBEIVC	-I-	-C-C	AC	-C-C	I	I	
HHVBC	-I-	-C-C	G	-G-A	I	I	
HHVCHA	-I-	-C-C	G	-G-A	I	I	
HBVATMIG	[REDACTED]	[REDACTED]	CCCCAG	-I	-I	-A-C	-A-C-GCA
HBVAXIC	[REDACTED]	[REDACTED]	CCCCAG	-I	-I	-A-C	-A-C-GCA
HBVATYC1	[REDACTED]	[REDACTED]	CA	A-CCCCA	I	I	-A-C-GCA
HBVATYC	[REDACTED]	[REDACTED]	CA	A-CCCCA	I	I	-A-C-GCA
HBVDNA	[REDACTED]	[REDACTED]	CA	A-CCCCA	I	I	-A-C-GCA
HPBIRVAAV	[REDACTED]	[REDACTED]	CA	A-CCCCA	I	I	-A-C-GCA
XXIEPAV	[REDACTED]	[REDACTED]	CA	A-CCCCA	I	I	-A-C-GCA
HBVORFS	[REDACTED]	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA
HHVBEC4	-I-	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA
HHVBEC	-I-	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA
HHVBBS	-I-	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA
HHVBF	-I-	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA
HHVBFQH	-I-	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA
HBVADWKA	-I-	[REDACTED]	CA	CCCCAG	I	I	-A-C-GCA

21/28

HBVXPS HBVADW HVHEPB S50225 HPBANZCG HPBADH3 HPBADW1 HPBADW2 HPBCADR HBVADRH HPBADA HPBCG HEHBVATR HBVADR HBVADR4 HPBADR1C HPBADRC HBVPREX HBET1NC HNVBC HNVCCIA HBVAYACG HBVAYTC HBVAYYE HBVONA NPBIIBVA XXHEPAV HBVORFS HBVBE4 HNVBBAS HNVBF HNVBFQU HBVADHKA	1001 AAGGACCACGCCAGAGCAACCAAGTAGGAGTGGGAGGATTCGGGCAAGGCACCCCTCACGGCGTAAATTGGGGCTAGGGCTAGGGCATATGGACACAGTGACAAATTCCTCTCTGGCTCACCAAT 15 33 58, 5 55 56 56
---	--

22/28


23/28

Figure 2: LiPA HBV design

LiPA line	Region	Purpose	HBPr	sequence
			Probe number/SEQ ID NO	
0		Pencil line		
1		biotinylated DNA		
2	PreS1	ampl. contr.	33	CTGAGGGCTCCACCCCA
3	PreS1	Genotype A	22	AACCTCGCAAAGGCAT
4	PreS1	Genotype A	50	CCCAGAGGGTTGGAAC
	PreS1	Genotype A	15	GCCAGCAGCCAACCAG
5	PreS1	Genotype B	57	CTGCATTCAAAGCCAACT
	PreS1	Genotype B	58	CCCCATGGGGACTGTTG
6	PreS1	Genotype B	59	CATACTACAACGTGCCA
7	PreS1	Genotype C	55	TTCAACCCCAACAAAGGATC
8	PreS1	Genotype C	54	TCAGGAAGACAGCCTAC
9	PreS1	Genotype D	92	TTCTGCCCATGCTGTA
10	PreS1	Genotype D	56	AATGCTCCAGCTCTAC
11	PreS1	Genotype D	73	TTCCACCAAGCAATCCTC
12	PreS1	Genotype E	60	GGGCTTTCTGGACGGTCC
	PreS1	Genotype E	61	CTCTCGAATGGGGAAAGA
	PreS1	Genotype E	62	CCTACCCAAATCACTCCA
13	PreS1	Genotype F	63	AGCACCTCTCAACGACA
14	PreS1	Genotype F	64	GCAAATTCCAGCAGTCCCG
	PreS1	Genotype F	65	GCCAATGGCAAACAAGGTA
15	preCore	promotor	88	TAGGTTAAAGGTCTTGT
16	preCore	promotor	89	TAGGTTAATGATCTTGT
17	preCore	scan codon -2 to +3	12	AAGTTGCATGGTGCTG
18	preCore	scan codon 1 to 5	34	ATGCAACTTTTCACC
19	preCore	scan codon 5 to 9	13	CACCTCTGCCCTAATCAT
20	preCore	scan codon 12 to 17	45	TGTACATGTCCCACGT
21	preCore	scan codon 12 to 17	46	TGTTCATGTCCCTACTGTT
22	preCore	scan codon 16 to 20	47	ACTGTTCAAGCCTCCAAG
23	preCore	scan codon 19 to 23	48	GGCACAGCTTGAGGGCTT
24	preCore	scan codon 23 to 27	49	AAAGCCACCAAGGCACA
25	preCore	codon 28 wt	9	TGGCTTTGGGCATGG
26	preCore	codon 28 mt	10	TGGCTTTAGGGCATGG
27	preCore	codon 28+29 mt	42	TGGCTTTAGGACATGGA

Figure 3

24/28



I = indeterminate; W = wild type; M = mutant

25/28

Figure 4

Genotyping in HBsAg

Genotype	Oligo	Sequence
A	HBPr 193	GGA TCA ACA ACA ACC AGT
	HBPr 140	CT CAA GGC AAC TCT ATG GG
	HBPr 77	CTA CGG ATG GAA ATT GC
B	HBPr 78	TAC GGA CGG AAA CTG C
	HBPr 153	CT CTA CTT CCA GGA ACA G
C	HBPr 154	C TGC ACG ATT CCT GCT
	HBPr 204	CT TTC GCA AGA TTC CTA TGG G
	HBPr 165	AC TCT ATG TAT CCC TCC T
D	HBPr 208	GC TGT ACC AAA CCT TCG GAT
	HBPr 172	G GGA CCC TGC CGA AC
E	HBPr 213	AG TGG TTC GCC GGG CTG G
	HBPr 216	CA GGA TCC ACG ACC ACC AGG
F	HBPr 219	GC TGT TCC AAA CCC TCG GAG
	HBPr 186	G CCA AAT CTG TGC AGC
	HBPr 148	CT TTC GCA AAA TAC CTA TG
A/B	HBPr 80	CTT CGG ACG GAA ATT GC
C/D/E	HBPr 177	ATG TTG CTG TTC AAA ACC TG
E/F		

Drug resistance in RT pol gene

Genotype	Oligo	Sequence	
A	HBPr 115	TCA GCT ATA TGG ATG ATG	wild type
	HBPr 116	TTC AGC TAT GTG GAT GAT	mutant
D	HBPr 127	TC AGT TAT ATG GAT GAT G	wild type
	HBPr 132	T TTC AGT TAT GTG GAT GAT	mutant


PreCore region

Genotype	Oligo	Sequence	
	HBPr 88	TAG GTT AAA GGT CTT TGT	promoter wild type
	HBPr 89	TAG GTT AAT GAT CTT TGT	promoter mutant
	HBPr 119	TGG CTT TGG GGC ATG	wild type codon 28
	HBPr 10	TGG CTT TAG GGC ATG G	mutant M2 codon 28
	HBPr 122	TGG CTT TGG GAC ATG G	mutant M4 codon 29
	HBPr 42	TGG CTT TAG GAC ATG GA	mutant M2/M4 codon

26/28

						29466	A
						29469	
						29457	B
						29464	
						29999	C
						29765	
						29651	D
						29435	
						29535	E
						29539	
						22298	F


Figure 5



27/28

Figure 6

	WT	Promotor	WT	WT	Codon 28
		MT		M2	M4
			1 3020		
				1 3016	
					1 3017
					1 3018
					1 3019




L.P.A line
o = Pencil Line
1 = Biotinylated DNA

2 = procase promoter wild type
3 = procase promoter mut
4 = procase codon 28 wt
5 = procase codon 28 mut
6 = procase codon 29 wt
7 = procase codon 29 mut

Figure 7

HBV infected patient treated with lamivudine



INNOGENETICS - MUREX

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/70		A3	(11) International Publication Number: WO 97/40193 (43) International Publication Date: 30 October 1997 (30.10.97)
(21) International Application Number: PCT/EP97/02002 (22) International Filing Date: 21 April 1997 (21.04.97)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 96870053.4 19 April 1996 (19.04.96) EP (34) Countries for which the regional or international application was filed: BE et al.		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): INNOGENETICS N.V. [BE/BE]; Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).		(88) Date of publication of the international search report: 7 May 1998 (07.05.98)	
(72) Inventors; and (75) Inventors/Applicants (for US only): STUYVER, Lieven [BE/BE]; Holestraat 8, B-9552 Herzele (BE). ROSSAU, Rudi [BE/BE]; Wilghoevestraat 45, B-2180 Ekeren (BE). MAERTENS, Geert [BE/BE]; Zilversparrenstraat 64, B-8310 Brugge (BE).			
(74) Agent: DE CLERCQ, Ann; Innogenetics N.V., Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).			
(54) Title: METHOD FOR TYPING AND DETECTING HBV			
(57) Abstract			
<p>The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from Figure 1, and with said probes being applied to known locations on a solid support and with said probes being capable of hybridizing to the polynucleic acids of the sample under the same hybridization and wash conditions, or with said probes hybridizing specifically with a sequence complementary to any of said target sequences, or a sequence wherein T of said target sequence is replaced by U; and detecting the hybrids formed; and inferring the HBV genotype and/or mutants present in said sample from the differential hybridization signal(s) obtained. The invention further relates to sets of nucleotide probes and possibly primers useful in said methods as well as to their use in a method for typing and/or detecting HBV and to assay kits using the same.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/02002

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 569 237 A (GEN-PROBE INC) 10 November 1993 see page 1, line 1 - page 2, line 30 ---	1,11,13, 14
X	WO 93 13120 A (CHIRON CORPORATION) 8 July 1993 see page 7, line 30 - page 10, line 35 see page 19, line 1 - page 26, line 34 see page 64 ---	1-8, 11-14
X	WO 95 02690 A (ABBOTT LABORATORIES) 26 January 1995 see page 3, line 25 - page 15, line 30 ---	1,11,13, 14
A	WO 91 10746 A (CHIRON CORP) 25 July 1991 see page 63; claim 64 ---	1-8, 11-14
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

2

Date of the actual completion of the international search Date of mailing of the international search report

22 October 1997

16.03.98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/02002

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 229 701 A (CETUS CORPORATION) 22 July 1987 see page 14; example 6 ---	1-8, 11-14
P,X	G.A. TIPPLES ET AL.: "Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro" HEPATOTOLOGY, vol. 24, no. 3, September 1996, PHILADELPHIA US, pages 714-717, XP002044246 cited in the application see the whole document ---	1-8, 12-14
P,X	R. LING ET AL.: "Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine" HEPATOTOLOGY, vol. 24, no. 3, September 1996, PHILADELPHIA US, pages 711-713, XP002044247 cited in the application see the whole document ---	1-8, 12-14
P,X	A. BARTHOLOMEUSZ ET AL.: "Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine" INTERNATIONAL ANTIVIRAL NEWS, vol. 5, no. 8, 1997, LONDON GB, pages 123-124, XP002044248 see the whole document -----	1-8, 11-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 97/02002

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-5, 11-14 all partially and 6, 7, 8 completely

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-5, 11-14 all partially and 6,7,8 completely

Method for genetic analysis of HBV using at least two nucleotide probes hybridizing specifically to a mutant HBV RT pol gene.

2. Claims: 1-5, 11-14 all partially

Method for genetic analysis of HBV using at least two nucleotide probes hybridizing specifically to a mutant HBV preCore region.

3. Claims: 1-5, 11-14 all partially

Method for genetic analysis of HBV using at least two nucleotide probes hybridizing specifically to a mutant HBsAg region.

4. Claims: 1-5, 11-14 all partially and 9,10 completely

Method for genetic analysis of HBV using at least two nucleotide probes hybridizing specifically to a HBV genotype-specific target sequence.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 97/02002

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0569237 A	10-11-93	AU 683414 B AU 4368693 A CA 2135074 A JP 7506254 T WO 9322460 A		13-11-97 29-11-93 11-11-93 13-07-95 11-11-93
WO 9313120 A	08-07-93	CA 2124928 A EP 0618924 A JP 7502653 T		08-07-93 12-10-94 23-03-95
WO 9502690 A	26-01-95	AU 7326494 A EP 0785996 A JP 9501829 T		13-02-95 30-07-97 25-02-97
WO 9110746 A	25-07-91	CA 2070632 A EP 0510085 A JP 5503422 T US 5656731 A US 5629153 A		11-07-91 28-10-92 10-06-93 12-08-97 13-05-97
EP 0229701 A	22-07-87	AT 127857 T AU 606043 B AU 6710987 A CA 1279244 A DE 3751513 D DE 3751513 T DK 10787 A ES 2078214 T IE 69565 B JP 2576980 B JP 62217161 A JP 2574640 B JP 6233700 A US 5386022 A US 5594123 A US 5176995 A US 5008182 A		15-09-95 31-01-91 16-07-87 22-01-91 19-10-95 28-03-96 11-07-87 16-12-95 02-10-96 29-01-97 24-09-87 22-01-97 23-08-94 31-01-95 14-01-97 05-01-93 16-04-91